Abstract: Abdominal wall blocks rely on the spread of local anesthetic within musculoskeletal planes to anesthetize multiple small nerves or plexuses, rather than targeting specific nerve structures. Ultrasoundography is primarily responsible for the widespread adoption of techniques including transversus abdominis plane and rectus sheath blocks, as well as the introduction of novel techniques such as quadratus lumborum and transversalis fascia blocks. These blocks are technically straightforward and relatively safe and reduce pain and opioid requirements in many clinical settings. The data supporting these outcomes, however, can be inconsistent because of heterogeneity of study design. The extent of sensory blockade is also somewhat variable, because it depends on the achieved spread of local anesthetic and the anatomical course of the nerves being targeted. The blocks mainly provide somatic analgesia and are best used as part of a multimodal analgesic regimen. This review summarizes the anatomical, sonographic, and technical aspects of the abdominal wall blocks in current use, examining the current evidence for the efficacy and safety of each.

Essentials of Our Current Understanding: Abdominal Wall Blocks

Ki Jinn Chin, FRCP,* John G. McDonnell, MD, FCARCSI, †Brendan Carvalho, MD, ‡Aidan Sharkey, FCAI, †Amit Pawa, FRCA, § and Jeffrey Gadsden, MD, FRCP, FANZCA//

From the *Department of Anaesthesia, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada; †Department of Anesthesia, Clinical Sciences Institute, National University of Ireland, Galway, Ireland; ‡Department of Anaesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA; §Department of Anaesthesia, Guy’s and St Thomas’ Hospitals, London, United Kingdom; †Department of Anesthesiology, Duke University Medical Center, Durham, NC.

Accepted for publication October 12, 2016.

Address correspondence to: Ki Jinn Chin, FRCP, Department of Anaesthesia, Toronto Western Hospital, University of Toronto, Mcl. 2-405, 399 Bathurst St, Toronto, Ontario, Canada MST 2S8 (e-mail: gjasgenic@gmail.com).

The authors declare no conflict of interest.

Copyright © 2017 by American Society of Regional Anesthesia and Pain Medicine

ISSN: 1098-7339
DOI: 10.1097/AAP.0000000000000545

Regional Anesthesia and Pain Medicine • Volume 42, Number 2, March-April 2017
as the thickest of the 3 flat muscle layers (Fig. 3). Medial to the midclavicular line, the IOM tapers off into its aponeurosis and contributes to the formation of the rectus sheath.

The TAM originates on the internal aspect of the 7th to 12th costal cartilages, the thoracolumbar fascia, and iliac crest. As its name indicates, the fibers run transversely to insert on the linea alba and pubic tubercle. Like the EOM and IOM, it tapers off medially into an aponeurosis that blends with the others to form the rectus sheath (Fig. 1). The transition from muscle into aponeurosis occurs along a crescent-shaped line, and thus just inferior to the costal margin, TAM runs deep to rectus abdominis for a short distance before tapering off into its aponeurosis (Fig. 4).

The RAM is a paired muscle that originates on the pubic crest and symphysis and ascends vertically to insert on the xiphoid process and fifth to seventh costal cartilages (Fig. 1). It is encased within the rectus sheath and is attached to the anterior aspect of the rectus sheath by 3 or 4 transverse tendinous insertions. These insertions divide the anterior rectus sheath compartment into separate subcompartments, giving the RAM its “6-pack” appearance in thin muscular subjects and consequently impeding cranio-caudal spread of injectate. The posterior rectus sheath compartment, by comparison, is unsegmented and is thus a more logical place for local anesthetic injection.

Understanding the structure of the posterior abdominal wall is essential to the landmark-guided TAP block and the more novel US-guided abdominal wall blocks, such as the TFP block and QL block.

Of the 3 muscle layers of the anterolateral abdominal wall, the TAM and IOM taper off posteriorly into their origins from the thoracolumbar fascia. The EOM, on the other hand, ends posteriorly in a free edge, which abuts against the latissimus dorsi muscle (Fig. 6).

The thoracolumbar fascia is a complex tubular structure of blended aponeuroses and fascial layers that encases the deep muscles of the back and, as its name suggests, extends from the lumbar to thoracic spine.\(^1,2\) Tracing it laterally from its anchor point on the spinous processes and supraspinous ligament, the thoracolumbar fascia splits into 3 layers: the posterior and middle layers enclose the paraspinous (erector spinae) muscles, and the middle and anterior layers enclose the QL muscle (QLM), which is a quadrilateral

---

**FIGURE 1.** Surface anatomy, muscular layers, and nerves of the anterolateral abdominal wall. The EOM and IOM and aponeuroses have been cut away on the right to show the TAP. The lateral cutaneous branches arise from their respective spinal nerves at or posterior to the midaxillary line and supply the skin of the lateral abdominal wall up to the midclavicular line. The T7-T9 nerves enter the TAP at or medial to the midclavicular line. Communicating branches between the spinal nerves give rise to plexuses of nerves within the TAP and the rectus sheath. The rectus sheath is deficient midway between the umbilicus and pubis. AAL indicates anterior axillary line; MAL, midaxillary line; MCL, midclavicular line; PAL, posterior axillary line.
muscle extending between the 12th rib and the (internal lip of the) iliac crest (Figs. 2 and 6). Medial and anterior to the QLM lies the psoas major muscle. The posterior and middle layers of thoracolumbar fascia fuse again lateral to the paraspinal muscles and merge with the aponeuroses of the IOM and TAM.

The transversalis fascia is a thin areolar tissue that lines the deep surface of TAM and separates it from the parietal peritoneum. It is 1 part of the larger endoabdominal fascia that lines the entire internal aspect of the abdominal wall. As such, it is continuous inferiorly with the fascia iliaca and medially with the investing fascia of QLM and psoas major muscle. The posterior and middle layers of thoracolumbar fascia fuse again lateral to the paraspinal muscles and merge with the aponeuroses of the IOM and TAM.1,2 The transversalis fascia is a thin areolar tissue that lines the deep surface of TAM and separates it from the parietal peritoneum. It is 1 part of the larger endoabdominal fascia that lines the entire internal aspect of the abdominal wall. As such, it is continuous inferiorly with the fascia iliaca and medially with the investing fascia of QLM and psoas major muscle. The posterior and middle layers of thoracolumbar fascia fuse again lateral to the paraspinal muscles and merge with the aponeuroses of the IOM and TAM.1,2

The triangular fossa is a thin areolar tissue that lines the deep surface of TAM and separates it from the parietal peritoneum. It is 1 part of the larger endoabdominal fascia that lines the entire internal aspect of the abdominal wall. As such, it is continuous inferiorly with the fascia iliaca and medially with the investing fascia of QLM and psoas major muscle. The posterior and middle layers of thoracolumbar fascia fuse again lateral to the paraspinal muscles and merge with the aponeuroses of the IOM and TAM.1,2

The transversalis fascia is a thin areolar tissue that lines the deep surface of TAM and separates it from the parietal peritoneum. It is 1 part of the larger endoabdominal fascia that lines the entire internal aspect of the abdominal wall. As such, it is continuous inferiorly with the fascia iliaca and medially with the investing fascia of QLM and psoas major muscle. The posterior and middle layers of thoracolumbar fascia fuse again lateral to the paraspinal muscles and merge with the aponeuroses of the IOM and TAM.1,2

The transversalis fascia follows the QLM and psoas major superiorly through the diaphragm, passing under the lateral and medial arcuate ligaments and blending with the endothoracic fascia of the thorax.4,5 These relationships of the thoracolumbar fascia, transversalis fascia and associated muscles have important implications for the potential spread of local anesthetic injected in the posterior abdominal wall.

The triangle of Petit (or inferior lumbar triangle) is the primary surface anatomical landmark for the TAP block. It is bordered inferiorly at its base by the iliac crest, laterally by the medial free edge of EOM and medially by the lateral edge of latissimus dorsi (Fig. 7). The triangle is covered superficially by skin and subcutaneous tissues, whereas its anterior (deep) floor is formed by IOM and the thoracolumbar fascia, which separates it from the fat-filled retroperitoneal space. However, cadaveric studies indicate that there is significant anatomic variability in the triangle of Petit.7,8 It was quite small in the majority of subjects (3.6 cm² on average7) and even absent in 18% of subjects because of overlapping of the free edges of EOM and latissimus dorsi.8 This inconsistency limits its usefulness as a reliable surface anatomical landmark.

Innervation of the Anterior Abdominal Wall

The anterior abdominal wall is innervated by the thoracoabdominal nerves and the ilioinguinal and iliohypogastric nerves (Fig. 1). The thoracoabdominal nerves originate from the anterior rami of the lower 7 thoracic spinal nerves (T6-T12) and are the continuation of the respective intercostal nerves. The T12 nerve is often also referred to as the subcostal nerve. They each give off a lateral cutaneous branch in the midaxillary line, which ascends to enter the subcutaneous tissues along the anterior axillary line and supplies the anterior abdominal wall. The upper segmental nerves T6-T9 only enter the TAP medial to the anterior axillary line (T6 enters it just lateral to the linea alba) and that the other nerves enter it progressively more laterally (Fig. 1).9 This has implications for the pattern of nerve involvement that can be expected by injection at different locations in the TAP. Within the TAP, the lower segmental nerves (T9-L1) give off multiple communicating branches...
to form a longitudinal TAP plexus, from which the terminal anterior branches arise. The terminal anterior cutaneous branches of the thoracoabdominal nerves enter the rectus sheath at its lateral margin (the linea semilunaris). In the vast majority of cases (89%), the nerves run deep to the posterior surface of RAM before ascending to pierce it 1.6 to 2.6 cm from its lateral edge. However, these nerves occasionally directly pierce the lateral edge of the RAM and thus may be missed by a rectus sheath block. Once again, the nerves branch and communicate to form a longitudinal rectus sheath plexus, before entering the subcutaneous tissue of the anterior abdominal wall.

The existence of TAP and rectus sheath plexuses indicates that individual terminal nerves have multiple segmental origins and that the traditional depiction of the cutaneous innervation of the abdominal wall in terms of well-demarcated dermatomes is not wholly accurate. This may be an explanation for the discrepancies between radiographically visualized spread of injectate in the TAP, apparent extent of clinical analgesia, and the cutaneous sensory block observed in studies. The iliohypogastric and ilioinguinal nerves are classically described as terminal branches of the anterior ramus of the L1 spinal nerve with occasional contribution from T12. Although this is true in the majority of individuals, there is significant variability, with up to 20% having origins from the L2 and L3 nerve roots. Both nerves emerge at the lateral border of psoas major and run inferolaterally on the ventral surface of QLM and TAM, just superior and parallel to the iliac crest (Fig. 2). The exact location at which the nerves pierce TAM and enter the TAP is variable.

Vasculature of the Anterior Abdominal Wall
There is a rich network of arteries and veins within the TAP, which supplies the anterior abdominal wall and promotes the absorption of local anesthetic injected in this plane. The main arteries are continuations of the lower thoracic intercostal arteries and the deep circumflex iliac arteries. Within the rectus sheath, bilateral superior epigastric arteries (continuations of the internal thoracic arteries) anastomose with the deep inferior epigastric arteries (which arise from the external iliac arteries) and are at risk of accidental puncture during rectus sheath block.
The landmark-guided TAP block was first described in 2001 and has since undergone multiple modifications. The "TAP block" is therefore a nonspecific term encompassing a heterogeneous group of approaches that share the common end point of local anesthetic injection into the neurovascular fascial plane superficial to the TAM. The aim in all cases is to block some or all of the lower thoracic spinal nerves (T7-T12) and the iliohypogastric and ilioinguinal nerves (L1). The approaches differ primarily in the site of needle insertion and injection, which, because of the complex course of the lower thoracoabdominal nerves and interplay between muscular and aponeurotic layers of the abdominal wall at different locations, leads in turn to differences in the spread of local anesthetic and extent of analgesia. There has been a lack of consistency in the terminology used to describe the different US-guided approaches and this review uses the nomenclature outlined in Table 1.

### TAP BLOCK

The landmark-guided TAP block was first described in 2001 and has since undergone multiple modifications. The "TAP block" is therefore a nonspecific term encompassing a heterogeneous group of approaches that share the common end point of local anesthetic injection into the neurovascular fascial plane superficial to the TAM. The aim in all cases is to block some or all of the lower thoracic spinal nerves (T7-T12) and the iliohypogastric and ilioinguinal nerves (L1). The approaches differ primarily in the site of needle insertion and injection, which, because of the complex course of the lower thoracoabdominal nerves and interplay between muscular and aponeurotic layers of the abdominal wall at different locations, leads in turn to differences in the spread of local anesthetic and extent of analgesia. There has been a lack of consistency in the terminology used to describe the different US-guided approaches and this review uses the nomenclature outlined in Table 1.

### Landmark-Guided TAP Block

#### Technique

The landmark-guided TAP block was first described by Rafi and later by McDonnell et al. Both authors describe the chief surface landmark as the insertion of the latissimus dorsi on the iliac crest. The site of needle insertion is immediately anterior to this "latissimiliac point (LIP)" and just superior to the iliac crest, in the triangle of Petit (Fig. 7). Given the variability in the size and presence of the triangle of Petit, the LIP may be a more accurate and consistent landmark.

McDonnell et al recommend seeking a "double-pop" as the end point for needle insertion, the first pop representing penetration of the EOM fascia and the second pop the deep fascia of IOM. Rafi, on the other hand, recommends contacting the external lip of the iliac crest and "walking" the needle tip over it until a single pop (penetration of the deep fascia of IOM) is obtained. Regardless, the subjective nature of tactile pops as end points for needle insertion may contribute to failure of the technique, particularly in inexperienced hands.

#### Pattern of injectate spread and sensory block

Radiological studies indicate that 20 to 40 mL of local anesthetic injected using the landmark-guided TAP approach will spread within the TAP from the iliac crest superiorly to the costal margin, anteriorly to the midaxillary line, and posteriorly to the lateral border of QLM. This TAP spread was thought to be responsible for block efficacy (hence the name) and has been the principle upon which subsequent modifications have been based. However, posterior extension of injectate spread into the plane between transversalis fascia and the ventral surface of QLM, and thence upward into the thoracic paravertebral space, has also been reported. It is postulated that this may be the more important mechanism for producing analgesia, particularly above the T10 level, because the T7-T9 nerves only enter the TAP medial to the anterior axillary line and close to the costal margin. This pattern of posterior and cranial spread is not seen with any of the US-guided TAP approaches, and they may therefore have little in common with the landmark-guided TAP block apart from the name.

The extent of cutaneous sensory block that can be achieved is less clear. McDonnell et al reported achieving a sensory block of the anterior abdominal wall from T7 to L1 in 6 volunteers (12 blocks), but the precise sites of sensory testing were not described. Carney et al mapped the extent of sensory loss in 8 blocks and found this was variable; in particular, blockade of the anterior
FIGURE 5. A, Sonoanatomy of the RAM and sheath in the supraumbilical region, with a corresponding schematic diagram showing the fascial and aponeurotic layers. The TAM is visible deep to the lateral edge of the RAM. Both the internal oblique aponeurosis and the transversus abdominis aponeurosis contribute to the posterior rectus sheath. The transversalis fascia and peritoneum lie deep to the posterior rectus sheath but cannot always be clearly distinguished as separate layers. B, Sonoanatomy of the RAM and sheath in the infraumbilical region below the arcuate line, with a corresponding schematic diagram showing the fascial and aponeurotic layers. Here, there is no posterior rectus sheath. The layer immediately deep to the perimysium of RAM is transversalis fascia. The aponeuroses of all 3 muscle layers contribute only to the anterior rectus sheath. EOA indicates external oblique aponeurosis; IOA, internal oblique aponeurosis; P, peritoneum; SC, subcutaneous tissue; TAA, transversus abdominis aponeurosis; TF, transversalis fascia.
FIGURE 6. Anatomy of the posterior abdominal wall and the US-guided QL block. The EOM ends in a free edge abutting the latissimus dorsi. The IOM and TAM end in aponeuroses that blend with the thoracolumbar fascia. The thoracolumbar fascia itself splits into 3 layers (posterior, middle, and anterior) that envelop the QLM and ESM. The QL block is performed by placing a curvilinear probe on the posterolateral aspect of the abdominal wall in a transverse oblique orientation, between the iliac crest and costal margin (blue line). Key landmarks for identifying the QLM are the VB, TP, and PMM. At the L3-L4 level, the large intestine in the peritoneal cavity may be seen deep to the abdominal wall muscles (as it is here); at the L2-L3 level, the kidney is usually visible in the retroperitoneal space. The circles indicate points for local anesthetic injection either anterior or posterior to QLM. ESM indicates erector spinae muscle; PMM, psoas major muscle; TP, transverse process; VB, vertebral body.

FIGURE 7. Line drawing of the surface anatomy of the abdominal wall, including the lumbar triangle of Petit (arrows). As can be seen from the diagram, the triangle is bounded posteriorly by the latissimus dorsi muscle and anteriorly by the external oblique with the iliac crest forming the base of the triangle. The floor of the triangle is formed by the IOM. Reproduced with permission from McDonnell et al. © 2017 American Society of Regional Anesthesia and Pain Medicine. Unauthorized reproduction of this article is prohibited.
<table>
<thead>
<tr>
<th>Block</th>
<th>Technique</th>
<th>Clinical Indication</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcostal TAP block</td>
<td>Probe position: placed lateral to xiphoid process; parallel to costal margin. Injection site: (1) Medial to linea semilunaris: deep to RAM and superficial to TAM where TAM tapers off medially into its fascial contribution to the posterior rectus sheath. (2) Lateral to linea semilunaris: deep to IOM and superficial to TAM. LA dosing: 0.2–0.3 mL/kg per block, concentration adjusted to keep within max recommended dose range (in mg).</td>
<td>Somatic analgesia for incisions in upper (T6-T7 to T9-T10) anterior abdominal wall.</td>
<td>Will not cover incisions lateral to anterior axillary line.</td>
</tr>
<tr>
<td>Oblique subcostal TAP block</td>
<td>Probe position: Midclavicular line to anterior axillary line; parallel to costal margin. Injection site: Extensive injection track in TAP, deep to IOM and superficial to TAM, along the entire costal margin. LA dosing: 0.2–0.3 mL/kg per block, concentration adjusted to keep within max recommended dose range (in mg).</td>
<td>Somatic analgesia for incisions in upper (T6-T7 to T9-T10) anterior abdominal wall.</td>
<td>Technically challenging needle insertion. Will not cover incisions lateral to anterior axillary line.</td>
</tr>
<tr>
<td>Lateral (midaxillary) TAP block</td>
<td>Probe position: Midaxillary line; parallel and superior to iliac crest. Injection site: Deep to IOM and superficial to TAM, in midaxillary line. LA dosing: 0.2–0.3 mL/kg per block, concentration adjusted to keep within max recommended dose range (in mg).</td>
<td>Somatic analgesia for incisions in lower (T10 to T12-L1) anterior abdominal wall.</td>
<td>Will not cover incisions lateral to anterior axillary line. L1 is not consistently covered.</td>
</tr>
<tr>
<td>Bilateral dual-TAP block</td>
<td>Combination of bilateral subcostal and lateral TAP blocks. LA dosing: 0.15–0.2 mL/kg per block, concentration adjusted to keep within max recommended dose range (in mg).</td>
<td>Somatic analgesia for extensive (T7-T12) incisions in anterior abdominal wall.</td>
<td>Will not cover incisions lateral to anterior axillary line.</td>
</tr>
<tr>
<td>IL-IH nerve block</td>
<td>Probe position: Posterior and superior to ASIS, parallel to the line between ASIS and umbilicus. Injection site: Medial to acoustic shadow of ASIS within the TAP. LA dosing: 0.1–0.15 mL/kg, concentration adjusted to keep within max recommended dose range (in mg).</td>
<td>Somatic analgesia for incisions in the right or left iliac fossa of the abdomen.</td>
<td>Visualization of nerves is not always possible or necessary.</td>
</tr>
<tr>
<td>Rectus sheath block</td>
<td>Probe position: Transverse orientation lateral to linea alba and just superior to umbilicus. Injection site: Medial to acoustic shadow of ASIS within the TAP. LA dosing: 0.1–0.2 mL/kg per side, concentration adjusted to keep within max recommended dose range (in mg).</td>
<td>Somatic analgesia for midline incisions in anterior abdominal wall.</td>
<td>Bilateral injections required. Divided injections superior and inferior to umbilicus may provide for better spread.</td>
</tr>
<tr>
<td>Anterior QL block</td>
<td>Probe position: Posterior axillary line, parallel to iliac crest. Injection site: Anterior (deep) to QLM. LA dosing: 0.2–0.3 mL/kg per block, concentration adjusted to keep within max recommended dose range (in mg).</td>
<td>Analgesia for midlower (T8-T12) incisions in anterior abdominal wall.</td>
<td>Needle may be inserted in lateral-to-medial direction or posterior-to-anterior (transmuscular approach). Lumbar plexus block may occur with the posterior-to-anterior (transmuscular) approach.</td>
</tr>
</tbody>
</table>
abdominal wall was patchy and incomplete. Areas that were consistently blocked were the area of injection, groin, and upper lateral thigh.

**US-Guided Lateral TAP Block**

**Technique**

The US-guided lateral TAP block was first described in 2007. Ultrasound allows direct visualization of the abdominal wall layers, needle placement, and local anesthetic spread in the TAP, and this was critical in popularizing the TAP block. Descriptions of the technique vary slightly in the published literature, but in general, the US transducer is placed in a transverse orientation midway between the costal margin and iliac crest and centered on the midaxillary line (Fig. 3). The needle is inserted in the anterior axillary line in-plane to the transducer and enters the TAP in the midaxillary line (Figs. 3 and 8). Although initially touted as a US-guided version of the landmark-guided TAP block, it is now clear that the US-guided lateral TAP is quite different with regard to where local anesthetic is injected. The point of needle entry into the TAP is anterior and superior to the LIP and triangle of Petit, which results in a different pattern of injectate spread.

**Pattern of injectate spread and sensory block**

Radiological studies indicate that the US-guided lateral TAP produces injectate spread confined to an area centered around the midaxillary line and that extends only as far as the costal margin, the iliac crest, and the anterior axillary line in most cases. Thoracoabdominal nerves that are consistently involved include T10, T11, T12, and, to a lesser extent, L1. T9 and above are usually not involved, as they enter only the TAP medial to the anterior axillary line.

The evidence for the extent of cutaneous sensory block is conflicting and may depend on whether assessment involves comprehensive area mapping or merely “point” testing using traditional dermatomal maps and surface landmarks. Studies using the latter approach indicate that craniocaudal coverage is variable, but the results are fairly consistent with the cadaveric dye studies. In general, the US-guided lateral TAP consistently provides blockade of the T11-T12 dermatomes and, in the majority of cases, also the T10 dermatome. Laterally, the block does not usually extend beyond the midclavicular or anterior axillary line, and this is attributed to failure to anesthetize the lateral cutaneous branches of the segmental nerves, which arise and leave the TAP posterior to the midaxillary line. Increasing the volume of injectate (eg, from 15 mL to 30 mL in an adult patient) does not appear to significantly increase the extent of spread.

On the other hand, in studies where the area of cutaneous sensory loss is systematically mapped out, this appears to be highly variable and to follow a nondermatomal distribution that does not extensively involve the anterior abdominal wall. Stoving et al observed a greater proportion of sensory loss (76% vs 24%) lateral to the line passing through the ASIS rather than medial to it, suggesting that the lateral cutaneous branches may be anesthetized after all. As in previous studies, the craniocaudal extent of sensory loss was confined to the infraumbilical area. There was evidence of significant blockade of the abdominal musculature, which may partly explain the discrepancy between the limited pattern of cutaneous sensory loss observed in this study and clinical reports of good analgesic efficacy. The nondermatomal pattern may be due to the aforementioned existence of a TAP plexus and overlapping contribution of multiple spinal nerves to individual terminal branches.
The US-guided subcostal TAP block was described in 2008 as a means of reliably providing analgesia of the supraumbilical abdominal wall (T6-T9) and is based on the fact that these nerves enter the TAP at the costal margin and medial to the anterior axillary line (Fig. 3). The original description involved insertion of a 100- to 150-mm needle into the TAP close to the xiphoid process, advancing it in an inferolateral direction and injecting local anesthetic parallel to the costal margin and as far as the anterior iliac crest. Alternatively, the needle may be inserted in the anterior axillary line and in a superomedial direction toward the xiphoid process; this allows preoperative placement of a catheter outside the surgical field.

This approach, subsequently termed the "oblique subcostal TAP block," requires a high degree of technical skill. Subsequent modifications include performing multiple separate injections along the costal margin or performing a single "point" injection either medial to the linea semilunaris (between RAM and TAM) or lateral to it (between IOM and TAM) (Fig. 9).

**FIGURE 8.** Ultrasound-guided lateral TAP block. A, Preinjection image. The US probe is placed in a transverse orientation between the costal margin and iliac crest in the midaxillary line. A needle is advanced in an anterior-to-posterior direction through the muscular layers of the abdominal wall to reach the TAP between IOM and TAM. The TAM has a characteristic darker hypoechoic appearance and is usually significantly thinner than the IOM. B, Postinjection image. Local anesthetic (LA) has distended the TAP, separating IOM and TAM. SC indicates subcutaneous tissue. Reproduced with permission from KJ Chin Medicine Professional Corporation.

**US-Guided Subcostal TAP Block Technique**

The US-guided subcostal TAP block was described in 2008 as a means of reliably providing analgesia of the supraumbilical abdominal wall (T6-T9) and is based on the fact that these nerves enter the TAP at the costal margin and medial to the anterior axillary line (Fig. 3). The original description involved insertion of a 100- to 150-mm needle into the TAP close to the xiphoid process, advancing it in an inferolateral direction and injecting local anesthetic parallel to the costal margin and as far as the anterior iliac crest. Alternatively, the needle may be inserted in the anterior axillary line and in a superomedial direction toward the xiphoid process; this allows preoperative placement of a catheter outside the surgical field.

This approach, subsequently termed the "oblique subcostal TAP block," requires a high degree of technical skill. Subsequent modifications include performing multiple separate injections along the costal margin or performing a single "point" injection either medial to the linea semilunaris (between RAM and TAM) or lateral to it (between IOM and TAM) (Fig. 9).

**Pattern of injectate spread and sensory block**

Cadaveric and volunteer studies support the potential to block the upper segmental nerves (T6-T9) as they emerge into the abdomen. However, the extent of sensory block seen with the subcostal TAP block is variable and may depend on where the local anesthetic is deposited in relation to where nerves emerge from under the costal margin into the TAP. Injection lateral to the linea semilunaris produces a block centered on T10-T11 and not extending higher than T9 most of the time. If T6-T8 coverage is desired, local anesthetic should be injected medial to the linea semilunaris, between RAM and TAM, and as close to the xiphoid process as possible. Even then, it appears difficult to achieve spread to T6 and T7 more than 50% to 70% of the time.
Injection that extends to the lateral aspect of the costal margin and iliac crest can produce a block that extends inferiorly to T12 and occasionally the L1 dermatome.

The lateral cutaneous branches are not blocked, and thus, incisional analgesia does not extend lateral to the anterior axillary line.

**US-Guided Bilateral Dual TAP Block Technique**

A combination of the US-guided subcostal and lateral TAP blocks, termed the US-guided bilateral dual-TAP block and involving a total of 4 injections, has been proposed as a method of providing analgesia to the entire anterior abdominal wall. In the original description, the subcostal block is performed by a “point” injection medial to the linea semilunaris, between RAM and TAM. Sondekoppam et al have recently proposed a modification that utilizes an extended needle track similar to the oblique subcostal approach and is designed primarily to allow the preoperative insertion of catheters outside the surgical field. Needle insertion occurs in a lateral-to-medial direction, starting at the anterior axillary line and traveling along the costal margin superiorly to reach the linea semilunaris. The needle is then withdrawn and inserted inferiorly toward the pubic symphysis and parallel to the inguinal ligament to provide coverage of the lower abdomen.

**Pattern of injectate spread and sensory block**

In their evaluations of the US-guided bilateral dual-TAP block, Berglum et al have shown that the lateral TAP block produces spread confined to the lower abdomen and a sensory block of T10-T12, whereas the subcostal TAP block produced spread in the upper abdominal TAP. By combining the two, they were able to consistently obtain a cutaneous sensory block of T9-T12 with extension to T7-T8 in the majority of subjects and occasionally as high as T6.

Sondekoppam et al evaluated their own modified technique in a small cadaveric study and similarly found dye spread involving T8 to L1 thoracoabdominal nerves in the majority of injections and spread to T7 in a small proportion. The lateral extent of dye spread was confined to an area between the anterior and midaxillary line, leading the investigators to conclude that the lateral cutaneous branches are unlikely to be covered in this approach.

**Surgical TAP Block**

Several surgical approaches to the TAP block have been described. In laparoscopic surgery, the surgeon inserts a block needle percutaneously, with entry into the TAP signaled by tactile pops and confirmed by visualization of inward bulging of the TAM as local anesthetic is injected. An alternative technique has been described in open abdominal surgery, where the wound edges are retracted and a needle inserted from the interior of the abdomen through the parietal peritoneum and into the TAP as signaled by a single tactile pop. Finally, a technique of surgical dissection into the TAP, followed by direct injection or placement of a catheter, has been described in abdominoplasty and abdominal flap breast reconstruction surgery. Advantages cited for the surgical approach include better matching of the site of injection to site of surgery, ease and speed of performance, and accuracy of injection into the correct tissue plane. There are no studies examining the spread of injectate with surgically placed TAP blocks or catheters, and most of the clinical data come from case series and retrospective case-control studies. Although the latter suggest that surgical TAP blocks can reduce early postoperative pain, further research is needed to confirm these findings.
opioid requirements and improve pain scores, the limited randomized controlled trial (RCT) data available at present, mostly in the setting of laparoscopic abdominal surgery, indicate only a modest analgesic benefit compared with placebo. In particular, Lapmahapaisan et al failed to show analgesic benefit in pediatric open abdominal surgery, which they attributed to the limited ability of their TAP block to cover subcostal incisions.

**Clinical Efficacy of the TAP Block**

A recent meta-analysis of US-guided TAP block (encompassing all approaches and surgery types) concluded that it confers a statistically significant but clinically modest analgesic benefit (mean reductions of 6 and 11 mg of intravenously administered [IV] morphine at 6 and 24 hours, respectively) in adult patients undergoing abdominal laparotomy, laparoscopy, or cesarean delivery. A similar meta-analysis of pediatric TAP and rectus sheath blocks also reported analgesic benefit but only in the early postoperative period (first 6-8 hours). The authors in both articles rightly note that their findings should be viewed with caution in view of the pronounced heterogeneity in the included studies and their analysis. As presented previously, different TAP block approaches produce different patterns of local anesthetic spread, which may in turn influence analgesic efficacy. This caveat must be borne in mind when interpreting the overall evidence for clinical efficacy of the TAP block in various surgical settings and may be partly responsible for some of the conflicting data. In particular, the landmark-guided TAP block appears to have a different mechanism of action from the US-guided TAP blocks. The posterior and cranial spread to the thoracic paravertebral space demonstrated with the landmark-guided TAP block may produce superior analgesia and thus explain the preponderance of favorable analgesic outcomes in studies that used this approach. In the following section, we present a qualitative review of the evidence for the different TAP block approaches according to type of surgery, with data from the RCTs summarized in Table 2.

**Upper Abdominal Surgery**

**Major open upper abdominal surgery**

The US-guided subcostal TAP is preferred to the US-guided lateral TAP block in upper abdominal surgery because it is more likely to cover the supraumbilical dermatoes. For extensive surgery, both approaches may be combined as in the bilateral dual-TAP block. There are no published data on the efficacy of the landmark-guided TAP block specifically in upper abdominal surgery.

Four studies compared the postoperative analgesia provided by US-guided TAP blocks with thoracic epidural analgesia in major upper abdominal surgery. Two of these utilized bilateral subcostal TAP catheters inserted at the end of surgery and an intermittent bolus regimen of local anesthetic; one utilized a preincisional single-shot subcostal TAP block; and the fourth inserted preincisional bilateral dual-TAP catheters (4 in total, using the approach described by Sondekoppam et al) with continuous infusion of local anesthetic. On the whole, these studies indicate that subcostal TAP block is a useful alternative in upper abdominal surgery where epidural analgesia is contraindicated or undesirable and also has fewer adverse effects, particularly hypotension. Nevertheless, thoracic epidural analgesia is still likely to provide superior analgesia compared with the subcostal TAP block, particularly if the incision extends lateral to the anterior axillary line; if there is a large component of visceral pain, or if TAP catheters are not utilized to extend analgesic duration. Furthermore, TAP catheter insertion can be technically complex, time consuming, and associated with technical failure when inserted postoperatively because of disruption of the normal tissue planes.

**Lower Abdominal Surgery (Nonobstetric)**

**Major gynecological surgery including total abdominal hysterectomy**

Multiple studies have examined the role of bilateral TAP blocks in major open gynecological surgery, especially total abdominal hysterectomy. A 2013 meta-analysis of data from 4 published studies (one using the landmark-guided TAP block and the others using the US-guided lateral TAP block) reported that TAP blocks significantly reduced 24-hour opioid consumption and pain scores; no details on the TAP block technique and intraoperative or postoperative analgesic regimen were supplied, and it appears likely that multimodal analgesia was not administered. Albrecht et al, on the other hand, found that when added to a regimen of intraoperative ketorolac, local anesthetic infiltration of port sites, and postoperative acetaminophen a presurgical US-guided subcostal TAP block did not significantly reduce 24-hour opioid consumption, time to first analgesic request, or pain scores up to 48 hours. At this time, therefore, TAP blocks do not appear to be a useful addition to multimodal analgesia in this population.
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major upper abdominal surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ninaj et al., 52 2011</td>
<td>N = 62, open hepatobiliary or renal surgery (incision superior to T10)</td>
<td>Bilateral USG subcostal TAP catheters inserted at end of surgery. Intermittent boluses of 1 mg/kg 0.375% bupivacaine every 8 h for 72 h.</td>
<td>Postop patient-controlled epidural infusion of 0.125% bupivacaine + fentanyl 2 μg/mL at 6-12 mL/h.</td>
<td>Similar pain scores at rest and on coughing up to 72 h postop. Significantly (Sig) more tramadol use in TAP vs epidural group (median 400 mg vs 200 mg). 8 patients (30%) in the TAP group had pain from lateral incisions or drain sites.</td>
<td>Therapeutic success rate of 63% in TAP group vs 78% in epidural group (NS). Technical failure of TAP catheter insertion in 7%. 45% of TAP catheters had to be resited postop vs 7% of epidurals.</td>
</tr>
<tr>
<td>Wahba and Kamal, 66 2014</td>
<td>N = 44, upper abdominal surgery. Intraop: GA + IV fentanyl infusion. Postop: IV PCA morphine. No systemic MMA.</td>
<td>Bilateral USG subcostal TAP catheters inserted at end of surgery. Loading dose of 20 mL followed by 15 mL of 0.25% bupivacaine every 8 h for 48 h.</td>
<td>T9-T10 thoracic epidural, inserted preop. Postop: loading dose of 10 mL of 0.125% bupivacaine followed by infusion at 6-8 mL/h.</td>
<td>Sig higher pain scores at rest and on coughing up to 48 h postop in the TAP group. Sig more patients needing IV PCA morphine in TAP vs epidural group (100% vs 73%). Sig shorter time to first morphine dose in TAP vs epidural group (mean 210 vs 311 min). Sig higher morphine use on POD 1 in TAP vs epidural group (median 18 vs 12 mg) and POD 2 (median 11 vs 7 mg).</td>
<td>Sig longer time to flatus in TAP vs epidural group (mean 52 vs 45 h). Sig shorter time to ambulation in TAP vs epidural group (mean 48 vs 63 h). Sig lower incidence of hypotension in TAP vs epidural group (9% vs 46%). Lower patient satisfaction in TAP vs epidural group (median 1 vs 3 on 0- to 3-point scale).</td>
</tr>
<tr>
<td>Wu et al, 67 2013</td>
<td>N = 82, open radical gastrectomy. Intraop: GA + IV remifentanil infusion + IV sufentanil boluses every 1.5 h. Postop: IV PCA morphine. No systemic MMA.</td>
<td>Bilateral preincisional USG oblique subcostal TAP blocks with 20 mL of 0.375% ropivacaine.</td>
<td>GA group: no block, systemic analgesia only. TEA group: T8-T9 thoracic epidural, inserted preop. Intraop: Loading dose 8 mL 0.25% ropivacaine, followed by 5 mL 0.25% ropivacaine every 1 h. Postop: infusion of 0.125% bupivacaine + morphine 8 μg/mL at 5 mL/h.</td>
<td>TAP vs GA groups: Sig lower dynamic pain scores at 0-6 h in TAP group, but similar rest and dynamic pain scores up to 72 h. Sig less morphine use at 0-6 h (median 5 vs 8 mg) in TAP group, but similar at all other intervals up to 72 h. TAP vs TEA groups: Similar rest and dynamic pain scores up to 72 h. Similar morphine use at 0-6 h (median 5 vs 3 mg) but sig higher in TAP group at all other intervals up to 72 h.</td>
<td>Technical failure of epidural insertion in 2 patients (7%) in TEA group. Higher intraop ephedrine requirement and incidence of postoperative hypotension in the TEA vs TAP or GA group (21% vs 0% vs 0%).</td>
</tr>
<tr>
<td>Study</td>
<td>Intervention</td>
<td>Comparator</td>
<td>Analgesic Outcomes</td>
<td>Other Outcomes/Comments</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ganapathy et al,50 2015</td>
<td>Bilateral preincisional USG dual-TAP catheters (4 in total) using lateral-to-medial approach. Loading dose 20 mL of 0.5% ropivacaine at each catheter site, followed by infusion of 0.35% ropivacaine at 4–5 mL/h into the 2 catheters on each side using a Y-connector and elastomeric pump. Postop: IV PCA hydromorphone</td>
<td>T7-T8 or T8-T9 thoracic epidural analgesia (TEA), inserted preop and loaded with 0.25% bupivacaine 5 mL + 3 mL pm to achieve a T6-T12 sensory block. Intraop: infusion of 0.1% bupivacaine + hydromorphone 10 μg/mL at 8 mL/h. Postop: infusion of 0.1% bupivacaine + hydromorphone 10 μg/mL at 8 mL/h with 3 mL PCA bolus every 20 min pm for 72 h.</td>
<td>Similar rest and dynamic pain scores in both groups up to 72 h. Similar morphine use at 0-24 h in TAP vs TEA group (mean 14 vs 16 mg) and 48-72 h (13 vs 10 mg), but sig higher in TAP group at 24-48 h (13 vs 5 mg). Fewer patients with pain scores &gt;5/10 in TAP group (15% vs 29%, n.s.)</td>
<td>No block failures in either group. Similarly high patient satisfaction scores in both groups. Higher incidence of significant hypotension in TEA group (21% vs 0%). Longer block performance time in TAP group (mean 36 min vs 15 min).</td>
<td></td>
</tr>
<tr>
<td>Lapmahapaisan et al,56 2015</td>
<td>Group I: bilateral surgical TAP blocks with 0.5–1 mL/kg 0.25% bupivacaine at end of surgery.</td>
<td>Group II: Wound infiltration with 0.5–1 mL/kg 0.25% bupivacaine at end of surgery. Group III: No blocks.</td>
<td>No sig difference between groups in incidence of inadequate analgesia or proportion of pain-free patients. No sig difference in opioid use over 24 h or time to 1st analgesic use between groups.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bhatia et al,68 2014</td>
<td>Group I: Bilateral USG lateral TAP. Group II: Bilateral USG subcostal TAP Bolus injection of 15 mL 0.375% ropivacaine on each side; all blocks performed at end of surgery.</td>
<td>Group III: No blocks.</td>
<td>Sig lower rest and dynamic pain scores with (a) subcostal TAP vs no block up to 24 h; (b) lateral TAP vs no block up to 2 h; (c) subcostal TAP vs lateral TAP from 4-24 h. Lower 24 h tramadol use in subcostal TAP vs lateral TAP vs no block (mean 27 mg vs 89 mg vs 125 mg). Longer time to first request for opioid in subcostal TAP vs lateral TAP vs no block (mean 552 min vs 411 min vs 150 min).</td>
<td>No sig difference in nausea, vomiting, or sedation between groups. Mean dynamic pain scores (0–10) in patients receiving no block ranged from 2.5 to 4.2 during 1st 24 h.</td>
<td></td>
</tr>
</tbody>
</table>
Shin et al,69 2014 N = 45, laparoscopic cholecystectomy Intraop: GA + IV ketorolac 30 mg + IV fentanyl prn Postop: IV fentanyl, IV ketorolac 30 mg prn in PACU; IV nalbuphine 10 mg prn in ward. No MMA.

Group II: Bilateral USG lateral TAP Group III: Bilateral USG oblique subcostal TAP Bolus injection of 20 mL 0.375% ropivacaine per side; all blocks performed preincision.

Group 1: no blocks.

Sig lower rest and dynamic pain scores with (a) subcostal TAP vs no block up to 3 h; (b) lateral TAP vs no block up to 1 h; (c) subcostal TAP vs lateral TAP from 1–24 h. No sig difference in analgesic use between groups.

Oblique subcostal TAP tended to produce cutaneous sensory block from T9-T10 vs T12-L1 with lateral TAP (but not consistently seen). Mean dynamic pain scores (0-10) in patients receiving no block ranged from 3.0 to 4.7 at 3–24 h.

El-Dawlatly et al,70 2009 N = 42, laparoscopic cholecystectomy using 4 infraumbilical ports. Intraop: GA + sufentanil 0.1 μg/kg prn Postop: IV PCA morphine. No MMA.

Preincisional bilateral USG lateral TAP block with 15 mL 0.5% bupivacaine per side. Sig less intraop sufentanil in TAP group (mean 8.6 μg vs 23.0 μg). Sig less morphine use in 24 h in TAP group (mean 10.5 mg vs 22.8 mg). Pain scores not assessed.

Ra et al,71 2010 N = 54, laparoscopic cholecystectomy. Intraop: GA (TIVA) + remifentanil infusion. Postop: IV fentanyl 20 μg prn or IV ketorolac 30 mg prn in PACU, and IV ketorolac 30 mg every 8 h for 1st 24 h.

Preincisional bilateral USG lateral TAP blocks with 15 mL of LA per side. Group I: 0.25% bupivacaine. Group II: 0.5% bupivacaine.

Control group: no blocks.

Sig lower pain scores in both TAP groups vs control group up to 24 h. Similar pain scores between TAP groups. Fewer patients in either TAP group received ketorolac or fentanyl in PACU vs control. Fewer patients in either TAP group complained of sleep disturbance due to pain.

Petersen et al,72 2012 N = 74, laparoscopic cholecystectomy. Intraop: GA (TIVA) + remifentanil infusion + IV sufentanil 0.2 μg/kg at end of surgery. Postop: PO acetaminophen 1 g every 6 h, PO ibuprofen 400 mg every 6 h. IV morphine 2.5 mg pm in 1st 2 h; PO ketobemidone 2.5 mg prn in 2–24 h.

Preincisional bilateral USG lateral TAP with 20 mL 0.5% ropivacaine per side.

No blocks.

Sig reduction in dynamic and rest pain over 24 h (measured as area under curve). Sig lower morphine use in TAP vs control groups at 0–2 h (median 5 mg vs 7.5 mg). No sig difference in ketobemidone use in TAP vs control groups at 2–24 h (median 0 mg vs 5 mg).

Tolchard et al,73 2012 N = 43, laparoscopic cholecystectomy. Intraop: GA + fentanyl 3 μg/kg + acetaminophen 15–20 mg/kg + dicyclanil 0.5 mg/kg. Postop: IV fentanyl 20 μg prn in PACU; IM morphine, PO tramadol, or PO codeine and “non-opioid” analgesics in ward.

Preincisional unilateral USG subcostal TAP block with 1 mg/kg of bupivacaine (mean volume 22 mL).

Postoperative LA infiltration of port sites with 1 mg/kg bupivacaine (mean volume 21 mL).

Sig lower pain scores in TAP group up to 4 h. Similar number of patients required fentanyl in PACU but dose was sig lower in TAP group (median 0.9 μg/kg vs 1.5 μg/kg). Sig lower opioid use in TAP group over 8 h (median 9.2 mg vs 16.9 mg IV morphine equivalents).

Similar incidence of nausea and vomiting, and level of sedation between groups. Graphical data indicate that differences in pain score are most marked up to 8 h, but similar at 24 h.

Chen et al,74 2013 N = 40, laparoscopic cholecystectomy. Intraop: GA + IV fentanyl 0.5 μg/kg prn Postop: IV morphine 0.05 mg/kg prn. No MMA.

Preincisional bilateral oblique subcostal TAP with 20 mL of 0.375% ropivacaine per side.

IV morphine 0.1 mg/kg post-induction of GA.

No sig difference in intraop fentanyl use in TAP vs control groups (mean 24.5 vs 31.3 μg) or in postop morphine use (0.0 mg vs 0.4 mg).

No sig difference in sedation or nausea and vomiting between groups. Sig shorter time to extubation in TAP group (mean 10.4 min vs 12.4 min).
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ortiz et al, 2012</td>
<td>N = 74, laparoscopic</td>
<td>Preincisional bilateral USG TAP blocks with 15 mL of 0.5% ropivacaine per side.</td>
<td>Preincisional infiltration of port sites with total of 20 mL of 0.5% ropivacaine.</td>
<td>No sig difference in pain scores between groups up to 24 h. No sig difference in intraop fentanyl use in TAP vs control groups (mean 237 vs 245 μg), intraop morphine use (mean 5.0 vs 5.8 mg), or 24 h morphine use (16.1 vs 15.4 mg). Similar incidence of nausea between groups.</td>
<td></td>
</tr>
<tr>
<td>Bariatric surgery</td>
<td></td>
<td>Postoperative bilateral USG TAP blocks (not specified if subcostal or lateral) with 20 mL of 0.375% ropivacaine per side.</td>
<td>No blocks.</td>
<td>Sig lower pain scores in TAP vs control group up to 24 h. Pain scores were highest at 1 h (median 2 vs 4) and lowest at 24 h (0 vs 1). Sig lower tramadol use in TAP vs control group over 24 h (mean 9 mg vs 48 mg). Shorter time to ambulation in TAP vs control group (mean 6.3 h vs 8.0 h).</td>
<td></td>
</tr>
<tr>
<td>Sinha et al, 2013</td>
<td>N = 100, laparoscopic</td>
<td>Preincisional bilateral USG subcostal TAP blocks with 30 mL of 0.25% bupivacaine per side.</td>
<td>No blocks.</td>
<td>Similar rest and dynamic pain scores up to 48 h. No sig difference in 24 h opioid use in TAP vs control group (mean 32.2 mg vs 35.6 mg IV morphine equivalents). No sig difference in time to 1st analgesic request in TAP vs control group (52 vs 25 min). Similar rates of nausea and vomiting, pruritus and length of hospital stay between groups.</td>
<td></td>
</tr>
<tr>
<td>Albrecht et al, 2013</td>
<td>N = 57, laparoscopic gastric bypass surgery.</td>
<td>Preincisional bilateral USG TAP blocks with 1.5 mg/kg of 0.75% ropivacaine (max 20 mL) per side.</td>
<td>Preincisional bilateral USG subcostal TAP blocks with 30 mL of 0.25% bupivacaine per side.</td>
<td>Sig lower rest pain scores in TAP vs control group at 6 h (median 2 vs 4), 24 h, (median 1 vs 3) and 36 h (median 1 vs 3). Sig lower morphine use in TAP vs control group over 24 h (mean 21.1 vs 39.6 mg) and over 48 h (26.8 vs 55.3 mg). Sig longer time to 1st PCA morphine request in TAP vs control group (median 45 vs 12.5 min). Sig lower rate of sedation in TAP vs control group (37% vs 63%). Similar rate and severity of nausea.</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>N</td>
<td>Type of Surgery</td>
<td>Anesthesia</td>
<td>Pain Management</td>
<td>Pain Scores</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>----------------</td>
<td>------------</td>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Atim et al, 2011</td>
<td>60</td>
<td>Total abdominal hysterectomy</td>
<td>GA + IV diclofenac 75 mg + IV tramadol 0.5 mg/kg</td>
<td>Preincisional bilateral USG lateral TAP blocks with 20 mL 0.25% bupivacaine per side</td>
<td>Lower rest and dynamic pain scores, and tramadol use in TAP vs control group up to 24 h. Similar rest and dynamic pain scores in TAP vs infiltration group up to 4 h, but lower in TAP group at 6 h and 24 h. Lower tramadol use in TAP group up to 24 h. Sig lower rest and dynamic pain scores in infiltration vs control group up to 4 h.</td>
</tr>
<tr>
<td>Griffiths et al, 2010</td>
<td>65</td>
<td>Major gynecological surgery via midline incision</td>
<td>GA + IV morphine 0.1–0.2 mg/kg + IV acetaminophen 1 g + IV parecoxib 40 mg</td>
<td>Bilateral USG lateral TAP blocks with 20 mL of 0.5% ropivacaine per side after wound closure</td>
<td>No sig difference in incidence of severe rest or dynamic pain (&gt; 5/10) at 2 h or 24 h. No sig difference in morphine use in TAP vs control groups at 2 h (mean 11.9 vs 13.5 mg) or 24 h (36 vs 34 mg).</td>
</tr>
<tr>
<td>Shin et al, 2011</td>
<td>32</td>
<td>Gynecological surgery via transverse incision</td>
<td>GA (TIVA) + remifentanil infusion</td>
<td>Preincisional bilateral USG lateral TAP block with 20 mL 0.375% ropivacaine per side</td>
<td>Sig lower pain scores in TAP vs control group at 2 h (mean 3.0 vs 5.2), 24 h (mean 0.9 vs 2.2) but not 48 h (0.4 vs 1.6). No sig difference in IV PCA use in TAP vs control group over 48 h (102 mL vs 108 mL). Lower rescue analgesic use in TAP vs control group.</td>
</tr>
<tr>
<td>Rojskjaer et al, 2015</td>
<td>46</td>
<td>Total abdominal hysterectomy</td>
<td>GA (TIVA) + remifentanil infusion + IV sufentanil 0.3 μg/kg at end of surgery</td>
<td>Preincisional bilateral USG lateral TAP block with 20 mL 0.75% ropivacaine per side</td>
<td>Sig lower rest pain scores in TAP vs control group at 2 h, and lower dynamic pain scores at 8 h. No sig differences in rest or dynamic pain at other time points. No sig difference in morphine use in TAP vs control group at 24 h (mean 36 vs 33 mg).</td>
</tr>
<tr>
<td>Gasanova et al, 2013</td>
<td>75</td>
<td>Total abdominal hysterectomy</td>
<td>GA + IV fentanyl 1–0.15 mg/kg</td>
<td>Group I: Bilateral USG lateral TAP blocks with 20 mL 0.5% bupivacaine per side at end of surgery + IV ketorolac 30 mg + postop MMA. Group II: TAP blocks at end of surgery only.</td>
<td>No sig difference in resting pain scores between groups over 48 h. Sig difference in dynamic pain scores between groups I and III, but not between groups I and II, or II and III. No sig difference in morphine use between groups at 24 h (1 vs II vs III: 38.4 vs 38.6 vs 42.6 mg).</td>
</tr>
<tr>
<td>Study</td>
<td>Standardized Management</td>
<td>Intervention</td>
<td>Comparator</td>
<td>Analgesic Outcomes</td>
<td>Other Outcomes/Comments</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>--------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Hotujec et al, 2015</td>
<td>N = 64, robotic-assisted laparoscopic gynecologic-oncologic surgery. Intraop: GA. No other analgesics given. Postop: “standard management” with IV + PO opioids and NSAIDs.</td>
<td>Preincisional unilateral USG lateral TAP block with 30 mL 0.25% bupivacaine.</td>
<td>Sham TAP block with 0.9% saline.</td>
<td>No sig difference in pain scores at 24 h in TAP vs control group (mean 6.44 vs 6.97). No sig difference in morphine use at 24 h in TAP vs control group (mean 64.9 vs 69.3 mg).</td>
<td>No sig difference in patient satisfaction with analgesia between groups.</td>
</tr>
<tr>
<td>Torup et al, 2015</td>
<td>N = 65, robotic-assisted laparoscopic hysterectomy. Preop: PO acetaminophen 1 g + diclofenac 50 mg or ibuprofen 400 mg. Intraop: GA (TIVA) + remifentanil infusion + IV morphine 0.2 mg/kg. Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h + diclofenac 50 mg or ibuprofen 400 mg every 8 h.</td>
<td>Preincisional bilateral USG lateral TAP block with 20 mL 0.5% ropivacaine per side.</td>
<td>Sham TAP blocks with 0.9% saline.</td>
<td>No sig difference in pain scores in TAP vs control group at 1 h (median 4.2 vs 4.0) or over 24 h (2.0 vs 2.1). No sig difference in morphine use at 24 h in TAP vs control group (median 17.5 mg vs 17.5 mg).</td>
<td>No sig differences in nausea or vomiting between groups.</td>
</tr>
<tr>
<td>Amr and Amin, 2011</td>
<td>N = 68, total abdominal hysterectomy. Intraop: GA + IV fentanyl 1 μg/kg pm Postop: IV morphine 20–50 μg/kg pm. No MMA.</td>
<td>Preincisional bilateral LMG TAP blocks with 20 mL 0.375% bupivacaine. Group II: TAP blocks at end of surgery.</td>
<td>Group III: Sham block.</td>
<td>Sig lower dynamic pain scores up to 48 h in both group I and II vs group III. Sig lower dynamic pain scores up to 48 h in group I vs II. Sig lower intraop fentanyl requirements in group I vs II vs III (mean 81 vs 170 vs 166 μg). Sig lower morphine use at 48 h in both group I and II vs group III (mean 21 mg vs 33 mg vs 66 mg). Sig longer time to first analgesic request in both group I and II vs group III (135 vs 120 vs 102 min).</td>
<td>Lower incidence of PONV in group I and II vs III (16% vs 29% vs 67%). Sig lower incidence of chronic pain in group I vs groups II and III. Failure of TAP block (absence of loss to cold sensation) was 6%. These patients were excluded from analysis.</td>
</tr>
<tr>
<td>Sivapurapu et al, 2013</td>
<td>N = 52, gynecological surgery (unspecified). Intraop: GA + IV fentanyl 0.5 μg/kg prn. Postop: IV PCA morphine. No MMA.</td>
<td>Bilateral LMG TAP block with 0.3 mL/kg of 0.25% bupivacaine per side at end of surgery.</td>
<td>Wound infiltration with 0.6 mL/kg of 0.25% bupivacaine.</td>
<td>Sig lower pain scores in TAP vs infiltration group up to 24 h. Sig lower morphine use in TAP vs infiltration group at 24 h (mean 22 vs 29 mg). Sig longer time to 1st analgesic use in TAP vs infiltration group (148 vs 85 min).</td>
<td>Sig lower incidence of PONV in group I and II vs III (16% vs 29% vs 67%). Sig lower incidence of chronic pain in group I vs groups II and III. Failure of TAP block (absence of loss to cold sensation) was 6%. These patients were excluded from analysis.</td>
</tr>
<tr>
<td>Study</td>
<td>N</td>
<td>Procedure</td>
<td>Intraop:</td>
<td>Postop:</td>
<td>Results</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------</td>
<td>--------------------------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>De Oliveira et al, 2011</td>
<td>75</td>
<td>Laparoscopic hysterectomy</td>
<td>GA + remifentanil infusion + IV hydromorphone</td>
<td>IV PCA hydromorphone + ibuprofen 600 mg every 6 h.</td>
<td>Sig lower pain scores for both groups I and II vs group III up to 24 h. Sig lower opioid use in group I vs both groups II and III over 24 h (median 7.5 vs 15 vs 15 mg IV morphine equivalents). Sig better quality of recovery scores in both group I and II vs group III.</td>
</tr>
<tr>
<td>Kane et al, 2012</td>
<td>58</td>
<td>Laparoscopic hysterectomy</td>
<td>GA + IV ketorolac 30 mg. Postop: IV PCA hydromorphone + ibuprofen 600 mg every 6 h.</td>
<td>IV PCA hydromorphone + ibuprofen 600 mg every 6 h.</td>
<td>No sig difference in pain scores in TAP vs control group at 2 h (median 5 vs 6) or 24 h (median 5 vs 5). No sig difference in morphine use in TAP vs control group on POD 0 (median 11.7 vs 11.8 mg) and POD 1 (median 7.5 vs 9.0 mg).</td>
</tr>
<tr>
<td>Calle et al, 2014</td>
<td>197</td>
<td>Outpatient laparoscopic hysterectomy</td>
<td>GA + remifentanil infusion + IV morphine prn Postop: IV morphine prn in PACU. PO acetaminophen 1 g every 6 h + PO ibuprofen 400 mg every 8 h post-discharge.</td>
<td>Bilateral surgical TAP blocks with 1.5 mg/kg bupivacaine in 20 mL per side at the end of surgery.</td>
<td>Sig lower pain scores at discharge in TAP vs control group (mean 3.8 vs 3.1). No sig differences in pain scores between groups at 24 h, 48 h, or 72 h. No sig differences in perioperative morphine use in TAP vs control group (mean 1.8 vs 1.49 mg).</td>
</tr>
<tr>
<td>Bhattacharjee et al, 2014</td>
<td>90</td>
<td>Total abdominal hysterectomy</td>
<td>GA + IV fentanyl 0.5 μg/kg prn + IV acetaminophen 1 g. Postop: IV tramadol 2 mg/kg prn for 1st dose then every 8 h + IV acetaminophen 1 g every 6 h.</td>
<td>Preinduction bilateral LMG TAP blocks with 0.5 mL/kg 0.25% bupivacaine per side.</td>
<td>Sig lower pain scores immediately postop in TAP vs control groups at rest (mean 0.3 vs 2.7) and on movement (median 0.8 vs 3.5). Sig lower intraop fentanyl use in TAP vs control group (median 81 vs 114 μg). Sig longer time to 1st analgesic use in TAP vs control group (median 290 vs 16 min).</td>
</tr>
<tr>
<td>Colorectal surgery</td>
<td></td>
<td>Open bowel resection</td>
<td>GA + IV morphine 0.15 mg/kg + PR diclofenac 1 mg/kg + PR acetaminophen 1 g Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h + PR diclofenac 100 mg every 18 h.</td>
<td>Bilateral LMG TAP with 20 mL 0.375% levobupivacaine per side.</td>
<td>Sig lower rest and dynamic pain scores in TAP vs control group during 1st 24 h. Sig lower morphine use in TAP vs control group at 24 h (mean 21.9 vs 80.4 mg). Sig longer time to 1st morphine use in TAP vs control group (157 vs 24 min).</td>
</tr>
</tbody>
</table>

Continued next page
<table>
<thead>
<tr>
<th>Study</th>
<th>N = 79, laparoscopic colorectal resection. Intraop: GA (details unspecified). Postop: IV PCA morphine + gabapentin 300 mg every 12 h + IV ketorolac 15 mg every 6 h + IV/PO acetaminophen 1 g every 6 h.</th>
<th>Bilateral surgical TAP block with 0.5 mL/kg 0.5% bupivacaine at end of surgery (max 30 mL).</th>
<th>Sham TAP blocks with 0.5 mL/kg 0.9% saline.</th>
<th>Sig lower pain scores in TAP vs control group in PACU (mean 2.1 vs 3.8). Sig lower pain scores in TAP vs control group throughout hospital stay. Sig lower hydromorphone use in TAP vs control group in PACU (mean 0.8 vs 1.8 mg). No sig difference between groups in opioid use beyond PACU.</th>
<th>No sig difference in TAP vs control group in hospital length of stay (mean 3.15 vs 2.87 d) or return to normal function (7.8 vs 10.8 d).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keller et al,62 2014</td>
<td>Preop: diclofenac 100 mg + gabapentin 300 mg. Intraop: GA (details unspecified). Postop: IV PCA morphine + gabapentin 300 mg every 12 h + IV ketorolac 15 mg every 6 h + IV/PO acetaminophen 1 g every 6 h.</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 1 mg/kg levobupivacaine (max 75 mg) per side.</td>
<td>No TAP block.</td>
<td>No sig difference in rest and dynamic pain scores between groups at all time points up to 24 h. Sig lower morphine use in TAP vs control group at 24 h (median 40 vs 60 mg).</td>
<td>No sig difference in hospital length of stay between groups.</td>
</tr>
<tr>
<td>Walter et al,92 2013</td>
<td>Intraop: GA + IV morphine prn Postop: IV PCA morphine + IV acetaminophen 1 g every 6 h.</td>
<td>No TAP block.</td>
<td>No TAP block.</td>
<td>No sig difference in rest and dynamic pain scores between groups up to 48 h. Sig lower morphine use in TAP vs infiltration group at 24 h (16.6 vs 24.0 mg) and 48 h (23.6 vs 31.8 mg).</td>
<td>No sig difference in time to first flatus, first solid intake, first feaces between groups. No sig difference in hospital length of stay between groups.</td>
</tr>
<tr>
<td>Park et al,93 2015</td>
<td>Intraop: GA + remifentanil infusion. Postop: IV PCA morphine. No MMA.</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0.25% ropivacaine per side at end of surgery.</td>
<td>Wound and port site infiltration with 40 mL of 0.25% ropivacaine at end of surgery.</td>
<td>No sig difference in rest or dynamic pain scores between groups up to 48 h. No sig difference in rest or dynamic pain scores between groups up to 48 h. No sig difference in tramadol use in TAP vs epidural group at 48 h (median 125 vs 100 mg).</td>
<td>Catheter resited in 1 (3%) epidural vs 6 (17%) TAP patients. Therapeutic block failure in 4 (13%) epidural vs 2 (7%) TAP patients. Shorter time to removal or urinary catheter in TAP vs epidural group (44 vs 72 h). Sig higher No sig difference in time to get out of bed to pass flatus, hospital length of stay, between groups.</td>
</tr>
<tr>
<td>Niraj et al,94 2014</td>
<td>Intraop: GA + preincisional epidural at T9-T11 with 20 mL 0.25% bupivacaine. Postop: acetaminophen 1 g every 6 h + IV tramadol every 6 h + diclofenac 150 mg every 24 h prn. IV PCA morphine started if therapeutic block failure identified in PACU despite restitting of catheters.</td>
<td>Bilateral USG dual-TAP (four-quadrant) blocks with total of 2.5 mg/kg 0.375% levobupivacaine, followed by insertion of lateral TAP catheters. Postop: TAP infusion of 0.25% bupivacaine for 48 h (rate not specified).</td>
<td>Preincisional epidural at T9-T11 with 20 mL 0.25% bupivacaine. Postop: epidural infusion of 0.125% bupivacaine + 2 μg/mL fentanyl at 8–12 mL/h and PCA bolus of 2 mL every 30 min.</td>
<td>No sig difference in rest or dynamic pain scores between groups up to 48 h. No sig difference in tramadol use in TAP vs epidural group at 48 h (median 125 vs 100 mg).</td>
<td>Catheter resited in 1 (3%) epidural vs 6 (17%) TAP patients. Therapeutic block failure in 4 (13%) epidural vs 2 (7%) TAP patients. Shorter time to removal or urinary catheter in TAP vs epidural group (44 vs 72 h). Sig higher No sig difference in time to get out of bed to pass flatus, hospital length of stay, between groups.</td>
</tr>
<tr>
<td>McDonnell et al,95 2007</td>
<td>N = 61, laparoscopic colorectal resection. Intraop: GA + preincisional epidural at T9-T11 with 20 mL 0.25% bupivacaine. Postop: acetaminophen 1 g every 6 h + IV tramadol every 6 h + diclofenac 150 mg every 24 h prn. IV PCA morphine started if therapeutic block failure identified in PACU despite restitting of catheters.</td>
<td>Bilateral LMG TAP with 20 mL 0.375% levobupivacaine per side.</td>
<td>No TAP block.</td>
<td>Sig lower rest and dynamic pain scores in TAP vs control group during 1st 24 h. Sig lower morphine use in TAP vs control group at 24 h (mean 21.9 vs 80.4 mg). Sig longer time to 1st morphine use in TAP vs control group (157 vs 24 min).</td>
<td>Sig lower rest and dynamic pain scores in TAP vs control group during 1st 24 h. Sig lower morphine use in TAP vs control group at 24 h (mean 21.9 vs 80.4 mg). Sig longer time to 1st morphine use in TAP vs control group (157 vs 24 min).</td>
</tr>
</tbody>
</table>
**Appendectomy**

Carney et al, 1995 2010  
N = 40, open pediatric appendectomy. Intraop: GA + IV morphine 0.15 mg/kg + PR diclofenac 1 mg/kg + PR acetaminophen 20 mg/kg. Postop: PCA or nurse-administered IV morphine + PO acetaminophen 20 mg/kg + PR diclofenac 1 mg/kg.

Preincisional unilateral LMG TAP block with 0.3 mL/kg 0.75% ropivacaine.

Sham TAP block with 0.9% saline.

Sig lower rest and dynamic pain scores in TAP group vs control group during 1st 48 h. Sig lower morphine use in TAP vs control groups at 6 h time intervals up to 24 h. Sig lower cumulative morphine use in TAP vs control group at 48 h (mean 10.3 vs 22.3 mg). Shorter time to 1st morphine use in TAP vs control group (median 55 vs 16 min).

No sig difference in incidence of nausea or sedation between groups.

Ninj et al, 2009  
N = 47, open adult appendectomy. Preincisional unilateral Intraop: GA + IV morphine 0.1 mg/kg + IV acetaminophen 1 g. Postop: IV PCA morphine + PO acetaminophen 1 g + PO diclofenac 50 mg.

Preincisional unilateral USG lateral TAP block with 20 mL 0.5% bupivacaine.

No TAP blocks.

Sig lower rest pain scores in TAP vs control group at 30 min (median 2 vs 5) and 24 h (2 vs 4). Sig lower dynamic pain scores in TAP vs control group at 30 min (median 4.5 vs 8.5) and 24 h (5.2 vs 8). Sig lower morphine use in TAP vs control group (mean 28 vs 50 mg).

Sandeman et al, 2011  
N = 93, laparoscopic pediatric appendectomy. Intraop: GA + IV fentanyl 1 μg/kg + port-site infiltration with 0.5 mL/kg 0.2% ropivacaine. Postop: IV PCA morphine + PO acetaminophen 15 mg/kg.

Preincisional bilateral USG lateral TAP block with 0.5 mL/kg 0.2% ropivacaine.

No TAP blocks.

Sig lower pain scores in PACU in TAP vs control group (median 0 vs 2). No sig differences in morphine or other analgesic use between groups at 16 h. No sig difference in time to 1st analgesic use between groups.

No sig difference in PACU or hospital length of stay between groups.

Tanggaard et al, 2015  
N = 56, laparoscopic adult appendectomy Intraop: GA + remifentanil infusion + IV morphine 0.2 mg/kg + port-site infiltration of 20 mL of 0.25% bupivacaine. Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h + ibuprofen 400 mg pm for shoulder pain.

Preincisional bilateral USG dual-TAP blocks with 15 mL 0.375% ropivacaine per site (total 60 mL).

Sham TAP blocks with 15 mL 0.9% saline per site.

Sig lower pain scores over 1st 12 h in TAP vs control groups at rest (median 2.5 vs 3.1) and on sitting (median 3.4 vs 5.0). No sig difference in morphine use in TAP vs control group (median 10 vs 20 mg).

No sig difference between groups in nausea, vomiting, length of PACU stay.

Continued next page
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inguinal surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Petersen et al, 99 2013</td>
<td>N = 90, adult open inguinal hernia repair. Intraop: GA (TIVA) + remifentanil infusion + IV sufentanil 0.2 μg/kg Postop: IV morphine 2.5–5 mg prn in PACU + PO ketorolac 2.5 mg every 1 h prn + PO acetaminophen 1 g every 6 h + ibuprofen 400 mg every 6 h.</td>
<td>Group I: Preincisional unilateral USG lateral TAP block with 25 mL 0.75% ropivacaine + sham iliopsoas block + sham TAP block. Group II: Preincisional LMG II-IH block with 10 mL 0.375% ropivacaine + intraop infiltration with 40 mL 0.375% ropivacaine + sham TAP block. Group III: sham TAP block + iliopsoas block + infiltration.</td>
<td>No sig difference in pain scores over 24 h in TAP (I) vs infiltration (II) vs control (III) groups at rest (mean 2.2 vs 1.9 vs 1.5) and on coughing (4.1 vs 3.7 vs 3.7). Sig higher pain scores over 1st 6 h in TAP group (I) vs infiltration group (II) at rest (mean 2.5 vs 1.0) and on coughing (4.0 vs 1.7). No sig difference in opioid use over 24 h between groups.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sahin et al, 100 2013</td>
<td>N = 57, pediatric open inguinal hernia repair. Preop: PO acetaminophen 40 mg/kg Postop: PO acetaminophen 15 mg/kg prn + IV morphine 0.05 mg/kg prn</td>
<td>Preincisional unilateral USG lateral TAP block with 0.5 mL/kg 0.25% levobupivacaine.</td>
<td>Wound infiltration with 0.2 mL/kg 0.25% levobupivacaine at end of surgery.</td>
<td>Sig lower pain scores in TAP vs infiltration group between 2–16 h but not at 1 h or 20–24 h. Sig lower acetaminophen use in TAP vs infiltration group (mean 19.7 vs 53 mg/kg) Sig longer time to 1st analgesic use in TAP vs infiltration group (mean 17 vs 4.7 h)</td>
<td></td>
</tr>
<tr>
<td>Aveline et al, 101 2011</td>
<td>N = 273, adult open inguinal hernia repair. Preop: GA + IV acetaminophen 1 g + IV ketoprofen 100 mg + IV sufentanil 0.1 μg/kg prn. Postop: IV morphine 3 mg prn in PACU; PO morphine 20 mg every 6 h prn + PO acetaminophen 1 g every 6 h + PO ketoprofen 150 mg every 12 h.</td>
<td>Preincisional unilateral USG lateral TAP block with 1.5 mg/kg 0.5% levobupivacaine.</td>
<td>Preincisional LMG II-IH nerve block with 1.5 mg/kg 0.5% levobupivacaine.</td>
<td>Sig lower rest pain scores in TAP vs control group at 4 h, 12 h, 24 h No sig difference in rest or dynamic pain scores between groups in PACU, on POD1 and POD2. No sig difference in IV morphine use in PACU between groups (median 0 vs 0 mg). Sig lower PO morphine use in TAP vs control group over 48 h (median 3 vs 4 doses).</td>
<td>No sig difference in chronic pain at 6 mo between groups.</td>
</tr>
<tr>
<td>Fredrickson et al, 102 2010</td>
<td>N = 41, pediatric open inguinal surgery. Preop: PO acetaminophen 30 mg/kg. Intraop: GA + IV fentanyl 0.25 μg/kg every 2 min prn. Postop: IV morphine 0.05 mg/kg or PO ibuprofen in DSU; PO acetaminophen 15 mg/kg prn + PO ibuprofen 10 mg/kg prn.</td>
<td>Preincisional USG lateral TAP block with 0.3 mL/kg of 1:1 mixture of 1% lidocaine + 1% ropivacaine.</td>
<td>Preincisional USG II-IH nerve block with 0.3 mL/kg of 1:1 mixture of 1% lidocaine + 1% ropivacaine.</td>
<td>Sig higher incidence of pain in DSU in TAP vs control group (76% vs 45%). Sig higher pain scores in TAP vs control group in DSU (median 4 vs 0.5). Sig higher rate of ibuprofen use in DSU in TAP vs control group (62% vs 30%). No sig difference in morphine use in DSU in TAP vs control group (24% vs 5%)</td>
<td>No sig difference in post-discharge ibuprofen use, comfort scores, or parental satisfaction between groups.</td>
</tr>
</tbody>
</table>
Open radical retropubic prostatectomy

Elkassabany et al., 2013

N = 32, ORRP. Intraop: GA + IV morphine 0.1–0.15 mg/kg + IV ketorolac 30 mg. Postop: IV PCA morphine. No MMA.

Preincisional bilateral USG lateral TAP block with 20 mL 0.5% bupivacaine. Sham TAP blocks with 0.9% saline.

Sig lower pain scores in TAP vs control group at 1 h (0 vs 6), 2 h (median 3 vs 6), and 6 h (median 3 vs 5). No sig difference in pain scores in TAP vs control group at 24 h (median 4 vs 4).

Sig lower morphine use in TAP vs control group at 0–1 h (median 0 vs 3.1 mg), 1–2 h (2 vs 4 mg), and 2–6 h (4 vs 5.1 mg); but not at 6–24 h (median 25 vs 20 mg).

Sig lower morphine use in TAP vs control group over 24 h (mean 25 vs 45.5 mg).

Skjelsager et al., 2013

N = 73, ORRP. Preop: PO acetaminophen 1 g + ibuprofen 600 mg + gabapentin 600 mg. Intraop: GA (TIVA) + remifentanil infusion + IV morphine 0.15 mg/kg. Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h + PO ibuprofen 600 mg every 8 h.

Group I: Bilateral USG lateral TAP block with 20 mL of 0.75% ropivacaine per side at the end of surgery + sham wound infiltration with 0.9% saline.

Group II: Surgical wound infiltration with 40 mL of 0.75% ropivacaine at the end of surgery + sham TAP block. Group III: sham TAP block + wound infiltration.

No sig difference in rest or dynamic pain scores over 24 h between groups. No sig difference in morphine use over 24 h in TAP vs infiltration vs control group (median 15 vs 15 vs 15 mg).

Plastic/reconstructive abdominal surgery

Zhong et al., 2014

N = 93, abdominal breast reconstruction. Intraop: GA + IV fentanyl 1 μg/kg prn. Postop: IV PCA hydromorphone + PO acetaminophen 1 g every 6 h.

Bilateral surgical TAP catheters inserted after abdominal flap harvest. Intermittent bolus of 0.2 mL/kg 0.25% bupivacaine every 8 h starting at the end of surgery until morning of POD3.

Placebo injections of 0.9% saline through catheter.

No sig difference in daily patient-reported rest or dynamic pain scores over 48 h between groups. Sig lower opioid use in TAP vs control group on POD 1 (mean 20.7 vs 30.0 mg IV morphine).

Renal transplantation

Soltani Mohammadi et al., 2014

N = 44, renal transplant recipients. Intraop: GA + IV fentanyl 1 μg/kg pm. Postop: IV PCA morphine. No MMA.

Preincisional unilateral USG lateral TAP block with 15 mL of 0.25% bupivacaine. Sham TAP block with 0.9% saline.

Sig lower pain scores in TAP vs control group at all time points from 1 h (median 1 vs 6) to 12 h (median 1 vs 3) up to 24 h (median 1 vs 2). Sig lower morphine use over 24 h in TAP vs control group (mean 10.8 vs 41.2 mg).
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freir et al., 2012</td>
<td>N = 65, renal transplant recipients. Intraop: GA + IV morphine 0.1 mg/kg + IV acetaminophen 1 g. Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h.</td>
<td>Preincisional unilateral LMG TAP block with 20 mL 0.375% levobupivacaine.</td>
<td>Sham TAP block with 0.9% saline.</td>
<td>No sig difference in dynamic pain scores over 24 h between groups. No sig difference in morphine use in TAP vs control group in PACU (mean 4.0 vs 3.1 mg) or over 24 h (mean 31.6 vs 32.6 mg).</td>
<td>Sig higher incidence of nausea in TAP vs control group (53% vs 24%).</td>
</tr>
<tr>
<td>Gulyam Kuruba et al., 2014</td>
<td>N = 54, renal transplant recipients. Intraop: GA = IV morphine 0.1 mg/kg pm + IV acetaminophen 1 g. Postop: IV PCA morphine + IV acetaminophen 1 g every 6 h.</td>
<td>Preincisional unilateral USG lateral TAP block with 20 mL 0.5% levobupivacaine.</td>
<td>Sham TAP block with 0.9% saline.</td>
<td>No sig difference in pain scores at any time point up to 24 h between groups. No sig difference in intraop morphine use in TAP vs control group (mean 1.76 vs 1.76 mg). No sig difference in morphine use at any time point up to 24 h between groups.</td>
<td>No sig difference in nausea, vomiting, or sedation between groups.</td>
</tr>
<tr>
<td>Hosgood et al., 2012</td>
<td>N = 46, laparoscopic donor nephrectomy. Intraop: GA (no details of intraop analgesia specified). Postop: IV PCA morphine.</td>
<td>Bilateral US-guided lateral TAP block with 20 mL 0.375% bupivacaine (no other details specified).</td>
<td>Sham TAP block with 0.9% saline.</td>
<td>Sig lower pain scores in TAP vs control group on POD1 (mean 1.9 vs 3.7) and POD (mean 1.1 vs 1.9) but not POD 3 (mean 1.2 vs 1.4). Sig lower morphine use in TAP vs control group at 6 h (mean 12.4 vs 21.2 mg). No sig difference in morphine use in TAP vs control group over total hospital stay (mean 45.6 vs 52.7 mg).</td>
<td>No significant difference in nausea, vomiting, hospital length of stay, or time to 1st fluid intake between groups.</td>
</tr>
<tr>
<td>Panikh et al., 2013</td>
<td>N = 60, laparoscopic donor nephrectomy. Intraop: GA + IM diclofenac 1.5 mg/kg. Postop: IV tramadol 1 mg/kg pm. No MMA.</td>
<td>Unilateral USG lateral TAP block with 25 mL 0.375% bupivacaine at the end of surgery.</td>
<td>Sham TAP block with 0.9% saline.</td>
<td>Sig lower rest and dynamic pain scores up to 12 h in TAP vs control group, but not beyond. Sig lower tramadol use at 24 h in TAP vs control group (mean 104 vs 236 mg). Sig longer time to 1st analgesic use in TAP vs control group (mean 547 vs 49 min).</td>
<td>No sig difference in nausea or sedation between groups.</td>
</tr>
</tbody>
</table>
However, multimodal analgesia was not administered in either study. In addition, Amr and Amin excluded failed blocks from analysis (6%), and Sivapurapu et al did not clearly specify the nature of surgery, which limit the conclusions that can be drawn from their results.

There are similarly conflicting data for TAP blocks in laparoscopic total hysterectomy. A small retrospective study found that US-guided lateral TAP blocks significantly reduced length of hospital stay and postoperative opioid consumption. This was supported by an RCT reporting that US-guided lateral TAP blocks significantly increased quality of recovery scores and reduced 24-hour opioid consumption and pain scores. However, more recent RCTs utilizing US-guided lateral TAP and surgically assisted TAP blocks failed to confirm these results, reporting no significant difference in quality of recovery, opioid consumption, and pain scores.

Taken together, the evidence suggests that while TAP blocks can contribute to postoperative analgesia the benefit is limited to the early postoperative period and is marginal when added to a multimodal regimen of NSAIDs and acetaminophen. One reason for this may be that TAP blocks, particularly the US-guided approach, are primarily effective for somatic pain, whereas major gynecological surgery is associated with a relatively large component of visceral pain.

Colorectal surgery

McDonnell et al showed early on that adding preoperative bilateral landmark-guided TAP blocks to a multimodal perioperative analgesic regimen of acetaminophen and NSAIDs significantly reduced pain scores and opioid consumption for up to 48 hours in open colorectal surgery. With regard to laparoscopic colorectal surgery, several retrospective reviews indicate that the addition of TAP blocks (US-guided and surgical) to a standard clinical pathway can reduce opioid requirements, as well as promote earlier return of bowel function and shorten length of hospital stay. Three recent RCTs confirm the analgesic efficacy of single-shot surgical and US-guided lateral TAP blocks in this setting, with reported reductions in pain scores and opioid consumption, particularly in the early postoperative period. This benefit was seen even in the presence of systemic multimodal analgesia or when compared with wound infiltration. Niraj et al performed a more complex TAP technique involving postoperative bilateral dual-TAP injections followed by insertion of bilateral US-guided lateral TAP catheters and compared this with a group who received thoracic epidural analgesia. Both groups received multimodal analgesia with NSAIDs and acetaminophen, and they had similar pain scores and opioid consumption; however, duration of urinary catheterization was significantly longer in the thoracic epidural group. None of the RCTs reported a significant difference between groups in time to return of bowel function or hospital discharge.

Appendectomy

The TAP block is well suited to open appendectomy because the incision is unilateral and within the T11-T12 dermatomes in the right iliac fossa. Its analgesic efficacy has been demonstrated in both pediatric and adult open appendectomy, using landmark-guided TAP and US-guided lateral TAP block approaches, respectively. In both studies, all patients received perioperative...
multimodal analgesia with NSAIDs and acetaminophen; nevertheless, the addition of a unilateral TAP block significantly reduced rest and dynamic pain scores, as well as opioid consumption up to 24 hours postoperatively.

The benefit is less clear in laparoscopic appendectomy, where pain is likely to have a larger visceral than somatic component. Bilateral US-guided lateral TAP blocks added to a regimen of intraoperative opioids, local anesthetic infiltration of port sites, and postoperative acetaminophen produced no analgesic benefit in a pediatric population.87 In adults, the same intervention produced a modest reduction in pain scores but not postoperative opioid consumption over the first 12 hours.96

**Inguinal hernia surgery**

The TAP block would also seem well suited to open inguinal hernia surgery, but the evidence for benefit is conflicting. Petersen et al99 studied 90 adult patients randomized to 1 of 3 groups: US-guided lateral TAP block, II-IH nerve block plus wound infiltration, and placebo. All patients received postoperative multimodal analgesia. Pain scores were low in all groups and not significantly different over 24 hours; however, pain scores over the first 6 hours were lower in the infiltration group compared with both the TAP and placebo groups. There was no significant difference in opioid consumption between the TAP group and the other 2 groups. By contrast, in pediatric inguinal hernia repair, unilateral US-guided lateral TAP block significantly reduced early postoperative pain and 24-hour cumulative analgesic use when compared with wound infiltration.100

Two other studies have compared US-guided lateral TAP block with II-IH nerve block. In the first, 273 adult patients received either a landmark-guided II-IH nerve block or US-guided lateral TAP block together with perioperative multimodal analgesia.101 Pain scores and opioid consumption were similar between groups in postoperative care unit (PACU), but the TAP group had lower pain scores at 4 to 24 hours and less opioid consumption over the first 2 postoperative days. A second smaller pediatric study20 used a US-guided technique for both TAP and II-IH blocks and found that almost twice as many TAP group patients had pain requiring analgesia in PACU; however, there were no significant differences in postdischarge analgesic use and pain scores.

It therefore appears that while the TAP block can provide effective early postoperative analgesia for open inguinal hernia repair, it does not confer a clinically significant benefit over an analgesic regimen incorporating systemic multimodal analgesia and wound infiltration. The severity of pain beyond 24 hours does not warrant a continuous TAP block technique.116 It is unclear how it compares with an II-IH nerve block, and this may depend on the block failure rate associated with the individual operator and the exact techniques used. Cadaveric and volunteer studies have indicated that the L1 dermatome may not always be blocked by the US-guided lateral TAP block,19,17 although this may be overcome to some extent by the use of larger volumes.

**Open radical retropubic prostatectomy**

A small case series of 12 patients undergoing open radical retropubic prostatectomy (ORRP) suggested that a multimodal analgesic regimen incorporating bilateral landmark-guided TAP blocks was associated with low pain scores and opioid consumption.118 Since then, 2 small RCTs have produced conflicting results. In patients receiving a single dose of intraoperative ketorolac, bilateral US-guided lateral TAP blocks significantly reduced pain scores and opioid consumption in the first 6 postoperative hours (but not beyond) compared with placebo, with an overall reduction in 24-hour opioid consumption.102 Skjelsager et al.103 on the other hand, compared 3 groups of patients receiving bilateral US-guided lateral TAP blocks, wound infiltration, or placebo and administered a perioperative multimodal analgesic regimen of gabapentin, NSAIDs, and acetaminophen to all patients. There was no difference between groups in pain scores or opioid consumption over the first 24 hours postoperatively. Therefore, while TAP blocks may improve early postoperative analgesia following ORRP, they are of minimal benefit if patients are receiving optimal multimodal analgesia.

**Plastic/reconstructive abdominal surgery involving the abdomen**

The analgesic efficacy of surgically performed TAP blocks has been investigated in both abdominoplasty and breast reconstruction using abdominal flaps. The evidence in abdominoplasty is derived from small case series and retrospective comparative studies but indicates that TAP blocks reduce early postoperative opioid consumption.57 However, they are less effective in larger flap resections, as in postbariatric abdominoplasty.119,120

In a retrospective case-control study of surgical TAP catheters in abdominal flap breast reconstruction, Zhong et al58 reported a significant reduction in 48-hour cumulative opioid consumption, but no difference in pain scores. They followed this with an RCT in the same population, in which TAP catheters were retained for 3 days.63 The reduction in opioid consumption, although statistically significant, was less impressive and confined to only the first postoperative day. Once again, there were no differences in pain scores or other secondary outcomes. The evidence therefore does not support the routine use of surgical TAP blocks in reconstructive abdominal surgery at this time.

**Renal transplantation**

The classic incision for renal transplant recipients extends from pubic symphysis to ASIS in the lower abdominal quadrant and would thus seem to be well suited to coverage by the TAP block. One RCT reported that a US-guided lateral TAP significantly reduced 24-hour opioid consumption and pain scores compared with placebo; however, patients did not receive any co-analgesics.164 In contrast, 2 other RCTs failed to show a significant impact of landmark-guided105 or US-guided lateral TAP106 on 24-hour opioid consumption or pain scores in patients receiving perioperative acetaminophen. Pain scores during the first 24 hours were low in all patients. Routine TAP blocks in this setting therefore appear to offer minimal additional benefit in patients receiving multimodal analgesia.

**Laparoscopic donor nephrectomy**

Three small RCTs have examined if US-guided lateral TAP blocks provide analgesic benefit in laparoscopic donor nephrectomy. Two of these indicate that both preincisional bilateral107 and postincisional unilateral168 US-guided lateral TAP blocks can reduce early postoperative pain scores and opioid consumption. The third study was unable to demonstrate any analgesic benefits of bilateral preincisional TAP blocks; however, it was underpowered (n = 21), and an unspecified number of patients received a supraumbilical rather than infraumbilical retrieval incision, which is unlikely to have been covered by the TAP block.109 None of the 3 studies utilized perioperative multimodal analgesia. Based on this limited evidence, TAP blocks may contribute to analgesia in the early postoperative period following laparoscopic donor nephrectomy, but the magnitude of benefit when added to a multimodal analgesic regimen is unclear.
Single-Shot Versus Continuous TAP Block

A major limitation of TAP blocks is the fixed duration of analgesia provided by a single-shot technique. Although pain scores and overall opioid consumption may be reduced in some settings for up to 24 to 48 hours,\textsuperscript{77,91} when block duration is measured by offset of sensory block or time to first request for rescue analgesia, volunteer and clinical studies of both landmark-guided\textsuperscript{77,90,91} and US-guided approaches\textsuperscript{13,28,121,122} indicate that this ranges from 6 to 10 hours on average with bupivacaine or ropivacaine. Although this can be overcome by placement of catheters in the TAP plane, either percutaneously or surgically, there are several issues to be considered.

The first is the question of timing of catheter insertion. Preoperative placement may require technical modification to avoid interference with the surgical field.\textsuperscript{50} Postoperatively, surgical wound dressings and disruption of tissue planes (eg, by surgery, air) can make percutaneous US-guided insertion difficult and contribute to a primary technical failure rate of 20% to 45%.\textsuperscript{52,94} Second, bilateral catheters are needed for incisions crossing the midline, which necessitates the use of either 2 infusion pumps or specialized tubing incorporating a Y-connector. Coverage of both supraumbilical and infraumbilical regions requires insertion and management of 4 separate catheters,\textsuperscript{50} which, although feasible, may be too complex for routine use. Third, there are no data to indicate whether a catheter dosing regimen of intermittent boluses\textsuperscript{52} or continuous infusion\textsuperscript{50,94} is preferable, what the optimal infusion rate is, and to what extent these choices are influenced by the TAP block technique and the type of surgery.

Finally, there is still relatively little evidence for the clinical benefit of continuous TAP blocks. It is unnecessary for surgery where postoperative pain is mild to moderate\textsuperscript{116} and may confer little additional benefit compared with single-shot TAP blocks.\textsuperscript{123} given that the latter often have an analgesic effect that outlasts clinically apparent block duration.\textsuperscript{124} Although TAP catheters are a logical alternative to epidural analgesia where this is contraindicated and may provide comparable analgesia,\textsuperscript{50,94} the technical and logistical issues involved would seem to preclude their widespread use.

Pharmacological Considerations for TAP Blocks

Long-acting local anesthetics such as bupivacaine, ropivacaine, and levobupivacaine are most commonly used for TAP blocks. There is wide variability in the doses used clinically in both adults and children, with reported total doses ranging between 2 and 3.5 mg/kg of ropivacaine and 1 and 2.5 mg/kg of bupivacaine.\textsuperscript{125–129} Volume is probably the primary consideration, given that the analgesic efficacy of TAP blocks is based on extent of spread, but there is little advantage in using volumes greater than 15 to 20 mL in adults.\textsuperscript{12,43,64} Local anesthetic concentrations should be subsequently selected to ensure that maximum recommended doses\textsuperscript{129,130} are not exceeded. Doses at the high end of the recommended ranges often result in potentially toxic local anesthetic plasma concentrations,\textsuperscript{131–133} and calculations should be based on lean rather than actual body-weight subjects.\textsuperscript{131}

At the same time, there is evidence that dilute concentrations (eg, 0.2%–0.25% ropivacaine) may be used without compromising efficacy.\textsuperscript{134,135} On balance therefore, reasonable dose and volume recommendations in adults would be 15 to 20 mL of 0.25% to 0.375% ropivacaine or 15 to 20 mL of 0.25% bupivacaine or levobupivacaine per side, with added epinephrine to reduce peak plasma concentrations.\textsuperscript{121,136} There are unfortunately much fewer pharmacokinetic and clinical data to guide dosing in children,\textsuperscript{126} and this is additionally confounded by the variation in size and age. A recent small RCT showed that a higher dose (2.5 vs 1.25 mg/kg of bupivacaine) was associated with a longer duration of analgesia.\textsuperscript{127} One suggested approach is to start with a weight-based mass of drug within maximum recommended limits and to calculate volume and concentration accordingly.

Two small RCTs have looked at the effect of adding dexamethasone\textsuperscript{137} and dexmedetomidine\textsuperscript{138} to the local anesthetic mixture when performing TAP blocks for abdominal hysterectomy. Both studies noted an increased time to first analgesic request (by 2–3 hours on average) and lower opioid consumption in the group that received the adjuvant drug compared with control subjects. Although these early results look promising, further research is needed before the use of these adjuvants to increase duration and quality of analgesia can be recommended. In contrast, the addition of clonidine to TAP blocks did not significantly affect acute postoperative analgesia or wound hyperalgesia in patients undergoing cesarean delivery.\textsuperscript{139}

Research has also begun into the use of liposomal bupivacaine in TAP blocks, which may offer a potential solution to the problem of limited analgesic duration with single-shot TAP blocks while retaining the simplicity of the technique. Early observational data support the efficacy of liposomal bupivacaine injected into the TAP,\textsuperscript{140,141} and a recent RCT of subcostal TAP block in robotic-assisted hysterectomy reported a significant difference in pain scores and opioid consumption over the first 48 hours in patients who received liposomal bupivacaine compared with plain bupivacaine.\textsuperscript{142}

II–IH NERVE BLOCK

Landmark-Guided Technique

Several different surface landmark-guided techniques have been described,\textsuperscript{11,143–147} all of which are based on needle insertion at a prespeciﬁed distance medial and inferior to the ASIS, with an end point of either 1 or 2 tactile fascial pops. Unfortunately, the course and location of the II and IH nerves with regard to the ASIS vary signiﬁcantly with age and between individuals.\textsuperscript{14,15,148} Cadaveric investigations in neonates have shown that the commonly used techniques are relatively inaccurate in pinpointing the II–IH nerves\textsuperscript{149} and that the nerves lie much closer to the ASIS (3 mm on average; 95% conﬁdence interval, 2.8–3.2 mm)\textsuperscript{148} than assumed.

The other major consideration is how to identify the correct tissue plane in which to inject. Posterior to the ASIS, the II and IH nerves lie in the TAP, although they often enter only the TAP close to the ASIS. Inferomedial to the ASIS, they ascend to pierce the IOM and lie in the plane between IOM and the EOM aponeurosis (Fig. 3). Most surface landmark–guided techniques recommend injecting in this latter plane, as signiﬁed by the single fascial pop of penetration of the EOM aponeurosis. However, the subtlety of this tactile end point\textsuperscript{150,151} combined with the thin muscular layers in children often leads to injection in the wrong layer. Weintraud et al\textsuperscript{150} sonographically evaluated the site of injection in children receiving a single-pop landmark-guided II–IH block and noted that only 14% were in the TAP. Of the rest, the injections were most often intramuscular in TAM or IOM and occasionally too deep (in iliacus muscle) or superficial (in EOM or the subcutaneous layer). Almost half of these blocks were ultimately unsuccessful.

Seeking 2 fascial pops and performing dual injection into both the TAP and the plane above have been advocated as a means of addressing the anatomical variation in the course of II and IH nerves. The dual-injection approach produced similar block success rates (approximately 78%) regardless of whether the injection was performed 1 cm inferomedial, 1 to 2 cm medial, or 2 cm medial to the ASIS in a pediatric population 2 to 12 years old.\textsuperscript{152}

© 2017 American Society of Regional Anesthesia and Pain Medicine | 159

Copyright © 2017 American Society of Regional Anesthesia and Pain Medicine. Unauthorized reproduction of this article is prohibited.
However, seeking a second fascial pop may increase the risk of exces-
ssively deep needle insertion and injection. Intraperitoneal injec-
tion leads to block failure and risks bowel perforation\textsuperscript{153,154}
and vascular injury.\textsuperscript{155} Injection deep to TAM can also lead to lo-
cal anesthetic tracking inferiorly under the fascia iliaca (which is con-
tinuous with the transversalis fascia) and thus causing femoral
nerve blockade.\textsuperscript{3}

Given the anatomical considerations outlined previously, it is
perhaps unsurprising that the failure rate of landmark-guided
II-IH blockade is as high as 20% to 40%, even in experienced
hands.\textsuperscript{21,22,152} and it is difficult to recommend 1 particular tech-
nique over any of the others. The most prudent approach would
seem to be to insert the needle slightly medial (3-10 mm depend-
ing on age) and inferior to the ASIS, through the EOM aponeuro-
sis (single pop), and to inject a relatively large volume to ensure
spread to the II and IH nerves.

**US-Guided Technique**

There are 2 locations at which the II and IH nerves may be visual-
ized and targeted on US (Fig. 2). The first is with the trans-
ducer placed medial to the ASIS and oriented along the
spinoumbilical line (between umbilicus and ASIS)\textsuperscript{156} In this
position, the EOM has usually transitioned into its aponeurosis, and
thus only 2 muscle layers are visible: IOM and TAM. Here, the
nerves either may lie in the TAP or may have already pierced IOM to lie superficial to it. The second and preferred approach is
to place the transducer superior and posterior to the ASIS.\textsuperscript{34,35}
Here, all 3 abdominal wall muscle layers are visualized, and both
nerves consistently lie in the TAP close to the iliac crest. The
ascending branch of the deep circumflex iliac artery and subcostal
nerve also lies in the TAP but in a more medial location. It is rela-
tively easy to learn to identify the ASIS and muscle layers (learning
curve <20 scans\textsuperscript{157}), but identification of the nerves is more chal-
lenging. However, if they cannot be visualized, it is usually suf-
cient just to inject 0.1 to 0.2 mL/kg of local anesthetic into the
TAP immediately medial to the ASIS (Fig. 2).

**US-Guided Versus Landmark-Guided II-IH Block**

The US-guided approach is recommended over the land-
mark-guided approach wherever possible.\textsuperscript{158} Its primary ad-
vantage is the ability to clearly visualize the abdominal wall lay-
ers (and often the nerves) and thus to deposit local anesthetic in the
appropriate plane. This translates into superior efficacy and safety,
as well as a reduction in the local anesthetic volume required
(Table 3).\textsuperscript{156} A dose-finding study has shown that administering
as little as 0.075 mL/kg of 0.25% levobupivacaine in a US-guided
II-IH block can provide analgesia for at least 4 hours postoper-
avatively following inguinal surgery.\textsuperscript{165} The safety advantage of
smaller volumes is particularly relevant as significantly higher
plasma ropivacaine concentrations were reported with the
US-guided versus landmark-guided approach following the
same dose of ropivacaine.\textsuperscript{22} This may be related to proximity
to the deep circumflex iliac vessels and more extensive spread
when local anesthetic is injected precisely into the TAP versus
injected intramuscularly.

**Clinical Efficacy of the II-IH Block**

The II-IH nerve block is a well-established regional anes-
thetic technique for inguinal surgery, for example, inguinal herni-
orrhapy, herniotomy, and orchidopexy. It is, however, a somatic
block and will not therefore cover visceral pain, for example, from
the spermatic cord. Pain in the territory of the genitofemoral nerve
may also impair the apparent success of the block. Anatomical
variation in the course of II and IH nerves and the multitude of
landmark-guided approaches to the II-IH block further contribute
to variability in reported block success rates. Despite this, land-
mark-guided II-IH blockade has been shown to be as effective
as caudal analgesia in pediatric inguinal surgery\textsuperscript{159–161} and avoids
many of the complications associated with the latter technique
(urinary retention, motor block, hypotension) (Table 3). On the
other hand, it does not offer additional analgesic benefit over sur-
gical wound infiltration in herniotomy surgery.\textsuperscript{162,163}

There are fewer data on the US-guided II-IH block, but Fredrickson
et al\textsuperscript{164} have shown that it is superior to the US-guided lateral TAP
block in pediatric inguinal surgery. In the setting of adult inguinal
hernia repair, the addition of a US-guided II-IH block to an analge-
sic regimen of intraoperative morphine and wound infiltration re-
sulted in superior analgesia in the early postoperative period.\textsuperscript{164}

**RECTUS SHEATH BLOCK**

**Landmark-Guided Rectus Sheath Block**

In the landmark-guided rectus sheath block, bilateral injec-
tions are performed medial to the linea semilunaris and just su-
erior to the umbilicus. Following skin puncture, a tactile pop
signals penetration of the anterior rectus sheath, and the needle
is advanced through the RAM until its tip lies just superficial to
the posterior rectus sheath, where 0.2 to 0.3 mL/kg of local anes-
thetic is injected. The original descriptions\textsuperscript{166,167} recommend
seeking a “scratching” sensation by a back-and-forth motion of
the needle as it is advanced, to confirm contact with the dense
anterior and posterior layers of the rectus sheath. Note that a
discrete fascial layer exists within the subcutaneous tissue\textsuperscript{168}
and may be mistaken for the anterior rectus sheath, particularly in
obese adults.\textsuperscript{169}

A “4-quadrant” injection approach has also been described,\textsuperscript{170}
in which bilateral injections are performed superior to the umbili-
cus, as well as inferior to it. Although this may theoretically improve
the longitudinal spread of local anesthetic, there are currently no
data to indicate if it provides superior analgesia. Blind injection
inferior to the arcuate line (approximately one-third to halfway
between the umbilicus and pubic crest) should be avoided because
the posterior rectus sheath is absent here (Fig. 4), and the risk of in-
advertent peritoneal puncture is consequently increased.

In yet another variation, the paraumbilical block, a subcuta-
neous injection is made on each side in addition to injection within
the rectus sheath.\textsuperscript{171} The aim is to anesthetize aberrant branches of
the anterior cutaneous nerves that do not pass through the rectus
sheath but instead pierce the rectus muscle directly or run superfi-
cial to the sheath. Once again, there are few clinical data on the ef-
cicacy of this approach.

**US-Guided Rectus Sheath Block**

In the US-guided rectus sheath block, the transducer is
placed in a transverse orientation just superior to the umbilicus
to visualize the linea alba and paired recti abdominis muscles
and then slid laterally to visualize the lateral aspect of the rectus
sheath and RAM (Fig. 4). The needle tip is placed between the
hyperechoic RAM and the hyperechoic posterior rectus sheath\textsuperscript{166,167},
injection in the correct plane will create a visible pool of local anes-
thetic separating the RAM from the rectus sheath (Fig. 10). The
superior and inferior epigastric arteries may be visible as hypo-
echoic pulsatile structures deep in the RAM\textsuperscript{172} and should be
avoided. The recommended injection volume is 0.1 to 0.2 mL/kg
(15–20 mL in adults) per side.\textsuperscript{166,167} Local anesthetic concentra-
tion should be adjusted as necessary to avoid exceeding maximum
recommended doses.
### TABLE 3. Summary of RCTs on II-IH Nerve Blockade

<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>US-guided vs landmark-guided II-IH block</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Willschke et al,156 2005</td>
<td>N = 100, pediatric open inguinal surgery. Intraop: GA + IV fentanyl 3 μg/kg prn. Postop: PR acetaminophen 40 mg/kg prn.</td>
<td>Preincisional unilateral USG II-IH block with 0.25% levobupivacaine “until both nerves were surrounded” by LA.</td>
<td>Preincisional unilateral LMG II-IH block (single “pop”) with 0.3 mL/kg 0.25% levobupivacaine.</td>
<td>Sig lower rate of intraop fentanyl use in USG vs LMG group (4% vs 26%). Sig lower rate of postop acetaminophen use in USG vs LMG group (6% vs 40%).</td>
<td>Sig lower vol of LA used in USG vs LMG group (mean 0.19 vs 0.3 mL/kg).</td>
</tr>
<tr>
<td>Weintraud et al,22 2009</td>
<td>N = 66, pediatric open inguinal surgery. Intraop: GA + IV fentanyl 1 μg/kg prn. Postop: no details given.</td>
<td>Preincisional unilateral USG II-IH block with 0.25 mL/kg 0.5% ropivacaine.</td>
<td>Preincisional unilateral LMG II-IH block (single “pop”) with 0.25 mL/kg 0.5% ropivacaine.</td>
<td>Sig lower rate of intraop fentanyl use in USG vs LMG group (6% vs 26%).</td>
<td>Sig faster resorption and higher plasma concentrations of LA in USG vs LMG group.</td>
</tr>
<tr>
<td>Markham et al,159 1986</td>
<td>N = 52, pediatric open inguinal surgery. Intraop: GA. No analgesics given. Postop: IM diamorphine 0.1 mg/kg prn.</td>
<td>Preincisional LMG II-IH block with 0.5 mL/yr (age) 0.5% bupivacaine.</td>
<td>Preincisional caudal block with 1 mL/yr (age) 0.5% bupivacaine.</td>
<td>No sig difference in intraop respiratory or hemodynamic parameters between groups. No sig difference in pain scores, postop analgesic use between groups.</td>
<td>Sig lower incidence of urinary retention at 6 h in II-IH vs caudal group (19% vs 46%).</td>
</tr>
<tr>
<td>Hannallah et al,160 1987</td>
<td>N = 44, pediatric orchidopexy. Intraop: GA. No analgesics given. Postop: IV fentanyl 1–2 μg/prn</td>
<td>Group I: LMG II-IH block with 4–6 mL 0.25% bupivacaine at the end of surgery.</td>
<td>Group II: Caudal block with 2.5 mL/yr (age) 0.25% bupivacaine at the end of surgery. Group III: no blocks.</td>
<td>No sig difference in pain scores in II-IH vs caudal group (median 1 vs 1).</td>
<td></td>
</tr>
<tr>
<td>Cross and Barrett,161 1987</td>
<td>N = 41, pediatric herniotomy and orchidopexy. Intraop: GA. No analgesics given. Postop: no details specified.</td>
<td>Preincisional LMG II-IH block + skin infiltration with 2 mL/kg 0.25% bupivacaine (max 20 mL unilateral and 40 mL bilateral block).</td>
<td>Preincisional caudal block with 1.0 mL/kg (herniotomy) or 1.25 mL/kg (orchidopexy) 0.25% bupivacaine.</td>
<td>No sig difference in pain scores in II-IH vs caudal groups at 1 h (mean 0.5 vs 0.3), 3 h (mean 0.6 vs 0.6), 6 h (mean 0.9 vs 0.6) or 18 h (mean 1.5 vs 1.2) No sig difference in postop analgesics required between groups.</td>
<td>No sig difference in vomiting, time to 1st micturition between groups.</td>
</tr>
<tr>
<td>Reid et al,162 1987</td>
<td>N = 49, pediatric herniotomy. Intraop: GA. No analgesics given. Postop: no details specified.</td>
<td>Preincisional LMG II-IH block (single “pop”) with 0.5 mg/kg 0.25% bupivacaine.</td>
<td>Wound infiltration with 0.5 mg/kg 0.25% bupivacaine at end of surgery.</td>
<td>No sig difference in intraop respiratory and hemodynamic parameters between groups. No sig difference in pain between groups up to 2 h postop. No sig difference in incidence of post-discharge pain reported by II-IH vs infiltration group (33% vs 19%).</td>
<td>No sig difference in mood, vomiting, sleep quality between groups.</td>
</tr>
<tr>
<td>Trotter et al,163 1995</td>
<td>N = 53, pediatric inguinal surgery. Intraop: GA. No analgesics given Postop: PO acetaminophen 15 mg/kg prn.</td>
<td>Preincisional LMG II-IH block (single “pop”) with 0.5 mL/kg 0.25% bupivacaine.</td>
<td>Wound infiltration with 0.5 mL/kg 0.25% bupivacaine at end of surgery.</td>
<td>No sig difference in pain scores between groups. No sig difference in postop analgesic use between groups.</td>
<td></td>
</tr>
</tbody>
</table>

Continued next page

© 2017 American Society of Regional Anesthesia and Pain Medicine. Unauthorized reproduction of this article is prohibited.
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fredrickson et al, 2010</td>
<td>N = 41, pediatric open inguinal surgery. Preop: PO acetaminophen 30 mg/kg. Intraop: GA + IV fentanyl 0.25 μg/kg every 2 min pm. Postop: IV morphine 0.05 mg/kg or PO ibuprofen in DSU; PO acetaminophen 15 mg/kg pm + PO ibuprofen 10 mg/kg pm.</td>
<td>Preincisional USG II-IH block with 0.3 mL/kg of 1:1 mixture of 1% lidocaine + 1% ropivacaine.</td>
<td>Preincisional USG lateral TAP block with 0.3 mL/kg of 1:1 mixture of 1% lidocaine + 1% ropivacaine.</td>
<td>Sig lower incidence of pain in DSU in II-IH vs TAP group (45% vs 76%). Sig lower pain scores in II-IH vs TAP group in DSU (median 0.5 vs 4). Sig lower rate of ibuprofen use in DSU in II-IH vs TAP group (30% vs 62%). No sig difference in morphine use in DSU in II-IH vs TAP group (5% vs 24%).</td>
<td>No sig difference in post-discharge ibuprofen use, comfort scores, or parental satisfaction between groups.</td>
</tr>
<tr>
<td>Aveline et al, 2011</td>
<td>N = 273, adult open inguinal hernia repair. Intraop: GA + IV acetaminophen 1 g + IV ketoprofen 100 mg + IV sufentanil 0.1 μg/kg pm. Postop: IV morphine 3 mg pm in PACU; PO morphine 20 mg every 6 h pm + PO acetaminophen 1 g every 6 h + PO ketoprofen 150 mg every 12 h.</td>
<td>Preincisional LMG II-IH nerve block with 1.5 mg/kg 0.5% levobupivacaine.</td>
<td>Preincisional unilateral USG lateral TAP with 1.5 mg/kg 0.5% levobupivacaine.</td>
<td>Sig higher rest pain scores in II-IH vs TAP group at 4 h, 12 h, 24 h No sig difference in rest or dynamic pain scores between groups in PACU, on POD1 and POD2. No sig difference in IV morphine use in PACU between groups (median 0 vs 0 mg). Sig higher PO morphine use in II-IH vs TAP group over 48 h (median 4 vs 3 doses).</td>
<td>No sig difference in chronic pain at 6 mo between groups.</td>
</tr>
<tr>
<td>Bærentzen et al, 2012</td>
<td>N = 74, adult open inguinal hernia repair. Intraop: GA (TIVA) + remifentanil infusion + IV morphine 0.2 mg/kg + wound infiltration with 15 mL 0.25% bupivacaine. Postop: IV morphine 2.5 mg pm in PACU; PO morphine 5 mg pm.</td>
<td>Preincisional USG II-IH block with 20 mL 0.5% bupivacaine.</td>
<td>Sham II-IH block with 0.9% saline.</td>
<td>Sig lower rest and dynamic pain scores in II-IH vs control group up to time of PACU discharge. No sig difference in pain scores on POD1 and POD2 between groups. No sig difference in opioid use on POD0 or POD1.</td>
<td>No sig difference in length of PACU stay, nausea and vomiting, and return to activities of daily living on POD1 and POD2.</td>
</tr>
</tbody>
</table>

All pain scores reported on a 0- to 10-point scale.

DSU indicates day surgery unit; GA, general anesthesia; intraop, intraoperative; LA, local anesthetic; MMA, multimodal analgesia; PCA, patient-controlled analgesia; postop, postoperative; PR, rectal; PO, oral; POD, postoperative day; pm, as needed; n.s., nonsignificant; TIVA, total IV anesthetic; USG, US-guided.
US-Guided Versus Landmark-Guided Rectus Sheath Block

As with II-IH nerve blockade, the chief advantage of the US-guided rectus sheath block is the ability to visualize the abdominal wall layers and appropriate plane for injection. Ultrasound significantly improved the precision of local anesthetic deposition into the rectus sheath by novices compared with the landmark-guided technique; however, the study (in an adult population undergoing laparoscopic surgery) did not report whether this resulted in superior analgesic efficacy. Ultrasound may also permit local anesthetic dose reduction; Willschke et al were able to provide highly effective intraoperative and postoperative (up to 4 hours) analgesia for pediatric umbilical hernia repair with 0.1 mL/kg of 0.25% levobupivacaine, instead of the 0.2 mL/kg usually recommended in the landmark-guided technique.

Surgical Rectus Sheath Block

Local anesthetic may be directly administered into the rectus sheath by the surgeon before wound closure, either as a single injection or through a catheter. Touted advantages include ease of performance, the lack of need for specialized anesthetic equipment and expertise, reduction in operating room times, accuracy, and improved congruency with the incision site.

Clinical Efficacy of the Rectus Sheath Block

The rectus sheath block has been used to provide somatic analgesia for midline incisions in a range of laparoscopic and open surgeries. It has been widely studied in umbilical hernia repair where data from case series indicate that it provides effective analgesia and may even be used for primary surgical anesthesia and in selected adult patients. However, it is controversial as to whether it offers significant analgesic benefit over simple surgical wound infiltration. The chief advantage of the rectus sheath block is that it can be performed before incision and thus reduce the need for intraoperative opioids. However, with regard to postoperative pain scores and opioid requirements, a small pilot study showed no difference, whereas 3 other RCTs reported only a modest reduction with single-shot rectus sheath block versus wound infiltration (Table 4). It should also be noted that none of the studies used an optimal multimodal analgesic regimen.

Similarly, while single-shot rectus sheath blockade can provide somatic analgesia for midline incisions associated with laparoscopic surgery (Table 4), it is unclear if it confers a clinically significant benefit over wound infiltration and systemic multimodal analgesia.

Rectus sheath block has been proposed as a useful technique in neonates undergoing pyloromyotomy. It provides similar postoperative analgesia compared with surgical wound infiltration, but more importantly, if administered prior to surgical incision, it allows sparing of intraoperative opioid and volatile anesthetic. This in turn minimizes the concerns of postoperative apnea and adverse effects on neurological development, respectively.

The greatest potential benefit may lie in continuous rectus sheath blockade following major laparotomy surgery; however, it is currently supported only by case reports and series. One small RCT has been published to date that showed no difference in opioid consumption or pain scores over a 48-hour period between patients receiving intermittent boluses of either bupivacaine or saline through bilateral, surgically inserted rectus sheath catheters following midline laparotomy. In contrast, 2 recent retrospective reviews of patients undergoing open colorectal surgery indicate that rectus sheath catheters may be as effective as epidural analgesia while offering a superior side-effect profile. A prospective RCT is in progress that may shed further light on the issue.

NEWER ABDOMINAL WALL BLOCKS

US-Guided Quadratus Lumborum Block

The US-guided QL block represents both the continued evolution of the US-guided TAP block and a return to the original intent of the landmark-guided TAP block approach. The promise of more extensive abdominal analgesia compared with the TAP block accounts for the growing interest in this block. The QL block uses the QLM as its principal sonographic landmark. This muscle, along with the tough thoracolumbar fascia that envelopes it, can be thought of as an anatomical bridge between the anterolateral musculature of the abdominal wall (EOM, IOM, TAM) and the lumbar paravertebral region (Fig. 6). It is easily imaged in most patients by placing a curvilinear transducer in a transverse orientation just above the iliac crest in the posterior axillary line. There are several descriptions regarding the ideal point of injection relative to the QLM, and this has led to some uncertainty.
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isaac et al, 2006</td>
<td>N = 13. Intraop: GA. No analgesics given. Postop: IV morphine 0.05 mg/kg prn.</td>
<td>Bilateral LMG rectus sheath block with 0.4 mL/kg 0.25% bupivacaine per side at end of surgery.</td>
<td>Wound infiltration with 0.8 mL/kg 0.25% bupivacaine at end of surgery.</td>
<td>No sig difference in pain scores between groups. No sig difference in morphine use in rectus sheath vs infiltration group (mean 0.1 vs 0.1 mg/kg).</td>
<td></td>
</tr>
<tr>
<td>Flack et al, 2014</td>
<td>N = 40, pediatric open umbilical hernia repair. Intraop: GA + IV fentanyl 1 μg/kg prn. Postop: IV morphine 30 μg/kg prn.</td>
<td>Preincisional bilateral USG rectus sheath block with 0.2 mL/kg 0.25% bupivacaine per side.</td>
<td>Preincisional IV fentanyl 2 μg/kg + wound infiltration with 0.4 mL/kg 0.25% bupivacaine at end of surgery.</td>
<td>No sig difference in max pain scores between groups. No intraop rescue analgesia required in either group. Sig lower morphine use in rectus sheath vs infiltration group (median 26.4 vs 58.5 μg/kg).</td>
<td></td>
</tr>
<tr>
<td>Gurnaney et al, 2011</td>
<td>N = 52, pediatric open umbilical hernia repair. Preop: PO acetaminophen 15 mg/kg. Intraop: GA + IV morphine 0.05 mg/kg prn. Postop: IV morphine 0.05 mg/kg prn or PO oxycodone 0.1 mg/kg.</td>
<td>Preincisional bilateral USG rectus sheath block with 0.25 mL/kg 0.25% bupivacaine per side.</td>
<td>Wound infiltration with 0.25 mL/kg 0.25% bupivacaine at end of surgery.</td>
<td>No sig difference in rest or dynamic pain scores between groups. Sig lower intraop morphine use in rectus sheath vs infiltration group (12% vs 54%). No sig difference in postop opioid use in rectus sheath vs infiltration group (mean 0.07 vs 0.1 mg/kg). Sig lower total opioid use in rectus sheath vs infiltration group (mean 0.07 mg/kg vs 0.13 mg/kg morphine).</td>
<td>No sig difference in nausea or vomiting between groups.</td>
</tr>
<tr>
<td>Dingeman et al, 2013</td>
<td>N = 52, pediatric open umbilical hernia repair. Intraop: GA + IV fentanyl 1 μg/kg + IV ketorolac 0.5 mg/kg. Postop: PO acetaminophen 12.5 mg/kg pm or IV morphine 0.05 mg/kg pm or PO codeine 1 mg/kg.</td>
<td>Bilateral USG rectus sheath block with 0.5 mL/kg 0.2% ropivacaine per side at the end of surgery.</td>
<td>Wound infiltration with 0.5 mL/kg 0.2% ropivacaine at end of surgery.</td>
<td>Sig lower pain scores in rectus sheath vs infiltration group in PACU. Sig more patients were pain-free in PACU in rectus sheath vs infiltration group. No sig differences in pain scores over 1st 24 h after discharge between groups. No sig difference in analgesic use in PACU or at home between groups.</td>
<td>No sig difference in length of PACU stay between groups.</td>
</tr>
<tr>
<td>Smith et al, 1988</td>
<td>N = 46, diagnostic gynecological laparoscopy. Intraop: GA. No analgesics given. Postop: IM papaveretum 0.3 mg/kg every 4 h pm.</td>
<td>Preincisional bilateral LMG rectus sheath block with 0.25 mL/kg 0.25% bupivacaine per side.</td>
<td>No rectus sheath block.</td>
<td>Sig lower pain scores in rectus sheath vs control group at 1 h (mean 7.1 vs 0.7), 6 h (mean 0.4 vs 4.3), 10 h (mean 1.6 vs 3.2). Sig lower need for postop rescue analgesia in rectus sheath vs control group at all time points up to 10 h.</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>N</td>
<td>Procedure</td>
<td>Intraop</td>
<td>Postop</td>
<td>Results</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>-----------</td>
<td>---------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>Azemati and Khosravi, 2005</td>
<td>9</td>
<td>Diagnostic gynecological laparoscopy</td>
<td>GA</td>
<td>No analgesics given</td>
<td>Group I: Bilateral LMG rectus sheath block with 10 mL 0.25% bupivacaine per side at the end of surgery. Group II: Intraabdominal instillation of 20 mL 0.125% bupivacaine in right subdiaphragmatic area at end of surgery. Group III: Wound infiltration with 10 mL 0.25% bupivacaine at end of surgery. Sig lower pain scores in rectus sheath group vs both groups II and III at 6 h (median 3 vs 7 vs 6) and 10 h (2 vs 5 vs 3). No sig difference in pain scores at 24 h between groups.</td>
</tr>
<tr>
<td>Hamill et al., 2015</td>
<td>130</td>
<td>Pediatric laparoscopic appendectomy</td>
<td>GA + IV morphine 0.3 mg/kg prn + IV fentanyl 2 μg/kg prn, acetaminophen 15 mg/kg + wound infiltration with 10 mL 0.25% bupivacaine. Opioids prn + “regular” acetaminophen + NSAIDs. Preincisional bilateral USG rectus sheath block with ≤ 2.5 mg/kg 0.25% bupivacaine (max vol 20 mL). No rectus sheath block. Sig lower pain scores in rectus sheath vs control group in 1st 3 h (mean 2.1 vs 3.9) but no sig difference thereafter. No sig difference in analgesic use between groups. Sig shorter time to PACU discharge in rectus sheath group. No sig difference in length of hospital stay, quality of life score or satisfaction between groups.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Padmanabhan et al., 2007</td>
<td>40</td>
<td>Adult midline laparotomy</td>
<td>GA: + IV morphine (dose not specified). Postop: IV PCA morphine. No MMA. Surgical insertion of rectus sheath catheter before wound closure, with bolus 20 mL 0.25% bupivacaine every 8 h for 48 h. Placebo bolus injections of 0.9% saline. No sig difference in mean pain score in rectus sheath vs control group on POD 1 (mean 2.24 vs 1.89) or POD 2 (2.22 vs 1.85). No sig difference in morphine use in rectus sheath vs control group in 0–24 h (mean 19.4 mg vs 21.4 mg) or in 24–48 h (30.5 vs 25.3 mg). Similar reductions in postoperative peak expiratory flow rate between groups.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All pain scores reported on a 0- to 10-point scale.

DSU indicates day surgery unit; GA, general anesthesia; intraop, intraoperative; LA, local anesthetic; MMA, multimodal analgesia; PCA, patient-controlled analgesia; postop, postoperative; PR, rectal; PO, oral; POD, postoperative day; prn, as needed; n.s., nonsignificant; TVA, total IV anesthetic; USG, US-guided.
about the manner by which the block exerts its effect as well as block nomenclature.

The QL block was first described in abstract form as a “no-pops” TAP block.\(^1\) While this report lacked a detailed description of the technique, a subsequent letter by Blanco and McDonnell\(^2\) provided clarification on the end point for needle advancement and outlined 2 separate versions of the QL block. The QL1 block was defined as an injection of local anesthetic adjacent to the lateral aspect of the QLM, immediately lateral to the tapered end of the TAM (Fig. 11). The needle is advanced in-plane in a lateral-to-medial direction to reach the plane between the IOM and TAM aponeurosis and the transversalis fascia. Injection here should result in visible spread along the anterior (ventral) surface of QLM, and some authors have described modifications that deliberately advance the needle tip into this location.\(^3,20\) In contrast, the QL2 block is an injection on the posterior (dorsal) surface of QLM, in the plane between QL and the investing layer of thoracolumbar fascia that separates it from the overlying latissimus dorsi or paraspinal muscles (Fig. 11). The needle approach is similar to the QL1, advancing in a lateral-to-medial direction through the oblique muscles with a shallower trajectory. Injectate administered at this point should be observed pooling along the posterior aspect of the QLM.

A third approach was described by Børglum et al.,\(^4\) in which the QLM is identified where it borders the psoas major and attaches to the transverse process of the L4 vertebra. The needle is inserted in a posterior-to-anterior direction through the QLM until the tip reaches the plane between the anterior surface of QLM and psoas major (Fig. 11). The authors termed this the transmuscular QL block, but it has also been termed the QL3 block.\(^20\)

The pattern of injectate spread with QL blocks appears distinct from those achieved following US-guided lateral or subcostal TAP blocks. Carney et al\(^20\) demonstrated in a small volunteer magnetic resonance imaging study that the QL1 block (which they called a posterior TAP block) resulted in pooling of contrast between the transversalis fascia, the QLM, and the psoas major, but noted a complete absence of spread to the TAP. Moreover, all subjects had some degree of thoracic paravertebral spread to at least the T10-T11 level and as high as T4-T5 in some cases. The transversalis fascia investing the QLM is continuous with the endothoracic fascia in the thorax,\(^20\) and it is suggested that this is the pathway for cranial extension of local anesthetic spread to the thoracic paravertebral space. This is at present the primary mechanism of action proposed for the QL block, but further anatomical and imaging studies are needed to confirm this, as well as whether the different QL block approaches result in similar patterns of spread.

The literature on QL blocks is still sparse. The early descriptions exist primarily as conference abstracts and e-letters, and most of our knowledge comes from case reports.\(^3,9,20,203,206\) Blanco et al\(^20\) recently published the first RCT of the QL2 block and demonstrated that when added to a multimodal analgesic regimen of acetaminophen and NSAIDs (but no intrathecal morphine) in patients undergoing elective cesarean delivery it reduced opioid requirements and pain scores in the first 24 to 48 hours. In another study, Murouchi et al\(^9\) compared a prospective cohort of 11 patients undergoing laparoscopic gynecologic surgery who received bilateral QL2 blocks to a historical cohort of patients who received bilateral TAP blocks. Those in the QL group had a significantly prolonged time to first request for rescue analgesia, with 8 of 11 subjects requiring no rescue analgesia in the first 24 hours. All of the subjects in the QL group had a sensory level from T8 to L1 (extending to T7 in just over half of subjects) compared with a sensory level of only T10 to L1 in the TAP group. This extensive cutaneous sensory block is consistent with case reports published to date.\(^3,9,20,203,206\) Promising results with continuous catheter techniques have also been reported for both children and adults.\(^3,9,20,203,206\) These early data are encouraging for the efficacy of the QL block, and further investigation is warranted.

Interestingly, the QL block may turn out to have utility beyond truncal analgesia. Because the transversalis fascia overlying the QLM extends caudally over psoas major and iliacus muscle, local anesthetic can spread to the lumbar plexus as well, and this has been confirmed in recent cadaveric studies.\(^20,208\) The efficacy of the QL block in hip surgery is supported by case reports\(^210,211\) and an RCT showing that patients who received a QL1 block for hip fracture surgery had better analgesia in the first 24 hours postoperatively compared with a low-volume US-guided femoral nerve block.\(^212\) This is also consistent with reports of cutaneous sensory block over the thigh with the landmark-guided TAP block\(^20\) and the L2 dermatome with the QL block.\(^20\) At the same time, this means that practitioners must be aware of the potential risk for unanticipated quadriiceps weakness and fall injury when performing QL blocks for abdominal surgery.

---

**FIGURE 11.** An illustration of 3 described approaches to the US-guided QL block. In the QL1 approach (1), the needle is advanced in a lateral-to-medial direction to reach the plane between the transversalis fascia (dotted line) and the internal oblique (IO) and transversus abdominis (TA) aponeurosis. In the QL2 approach (2), the same needle trajectory is used to reach the tissue plane posterior (dorsal) to QLM. In the transmuscular or QL3 approach (3), the needle is advanced in a posterior-to-anterior direction to reach the anterior (ventral) surface of QLM. EO indicates external oblique; ES, erector spinae; IO, internal oblique; LD, latissimus dorsi; PM, psoas major; TA, transversus abdominis.
Transversalis Fascia Plane Block

The US-guided TFP block was first described in 2009 as a technique for achieving proximal blockade of the T12 and L1 nerves, including their lateral cutaneous branches. In the TFP block, the transducer is placed in a transverse orientation just superior to the iliac crest, and the IOM and TAM are traced posteriorly until they are observed to taper off into their common aponeurosis and abut against the QLM. The needle is inserted in an anterior-to-posterior direction until the tip is deep to the tapered tip of the TAM. Injection occurs into the plane between the TAM and the transversalis fascia, creating a visible pocket of fluid (Fig. 12). Although this technique appears similar to the QL1 block, the point of injection is more caudal (adjacent to the iliac crest) and more anterior (deep to the muscular tip of TAM rather than the aponeurosis of TAM/IOM). This results in more localized spread, specifically targeting the II and IH nerves where they run deep to TAM before ascending into the TAP. At present, there are few published clinical data on the TFP block, apart from a small retrospective review demonstrating effective early postoperative analgesia in anterior iliac crest bone graft harvesting. As with the QL block, there is a potential risk of spread under transversalis fascia to the lumbar plexus with ensuing quadriceps weakness.

ABDOMINAL WALL Blocks in OBSTETRIC PATIENTS

The application of abdominal wall blocks in obstetric patients warrants a separate discussion because of the large body of literature dealing specifically with this patient population and the unique considerations for analgesia in cesarean delivery. The majority of modern cesarean deliveries are performed under neuraxial anesthesia with single-dose intrathecal or epidural morphine as the cornerstone of postoperative analgesia, supplemented with oral NSAIDs and acetaminophen. Neuromuscular blockade provides effective and prolonged (12-36 hours) analgesia for both incisional and visceral pain after abdominal surgery, whereas NSAIDs improve the visceral, cramping pain after cesarean delivery. Despite these analgesic interventions, pain is often incompletely relieved, and the majority of women will require additional opioid analgesia. Neuraxial opioids are also associated with adverse effects such as pruritus and nausea and vomiting, and the potential risk of delayed respiratory depression necessitates additional postoperative monitoring, all of which can present as a barrier to their use.

Abdominal wall blocks are therefore a valuable option in obstetric patients, especially as the intraumbilical Pfannenstiel incision of lower-segment cesarean delivery is ideally suited to coverage by TAP, II-III, or QL block. There is minimal concern regarding local anesthetic use and breast-feeding because most local anesthetics (particularly ropivacaine) have very limited breast milk transfer and are poorly bioavailable to the breast-feeding infant. These blocks should, however, be considered as adjuvants to, and not substitutes for, a multimodal analgesic strategy, because they are only effective against somatic incisional pain and do not prevent visceral uterine pain.

TAP Blocks in Obstetric Patients

Transversus abdominis plane blocks are the most frequently utilized and studied truncal block in the obstetric setting. Performing TAP blocks prior to delivery of the fetus is relatively contraindicated because of potential fetal injury and in utero exposure to local anesthetic drugs; they are therefore performed at the end of surgery after skin closure or as a rescue block in recovery. The US-guided lateral TAP block appears to be more popular than the landmark-guided TAP block, presumably because of concerns regarding accuracy of needle placement with the latter approach. It is currently unclear if one approach is more effective than another. Subgroup analysis in 1 meta-analysis has indicated that approaches using a more posterior injection site, such as the landmark-guided TAP block, may produce superior and more prolonged analgesia compared with the US-guided lateral TAP block. As previously discussed, this may be due to more extensive local anesthetic spread, particularly to the thoracic paravertebral space, in the former subgroup. However, the observed difference in effect size may also be due to the fact that none of the studies in the posterior injection subgroup utilized intrathecal morphine. In contrast, another meta-analysis that subdivided studies by whether intrathecal morphine was administered reported that both approaches were largely similar in analgesic efficacy, with any difference being in favor of the US-guided approach.

TAP block in cesarean delivery under general anesthesia

Evidence for the efficacy of TAP block for postoperative cesarean delivery analgesia depends on the clinical setting. For cesarean delivery performed under general anesthesia, studies have shown TAP blocks performed at the end of surgery reduce analgesic requirements, as well as pain scores (Table 5).

TAP block in cesarean delivery under neuraxial anesthesia

The analgesic efficacy of TAP blocks in cesarean delivery performed under neuraxial anesthesia depends on the utilization of intrathecal morphine. Pooled data from meta-analyses in women undergoing cesarean delivery under spinal anesthesia without intrathecal morphine show that TAP blocks are beneficial in the early postoperative period. Rest pain was reduced at 6, 12, and 24 hours but not at 48 hours, and dynamic pain was reduced at 6 and 12 hours but not 24 or 48 hours (Table 5). Transversus abdominis plane blocks also reduced opioid consumption at 6, 12, and 24 hours by 24 mg IV morphine on average, increased the time to first analgesic request by more than 2 hours, and increased satisfaction scores compared with control subjects. Studies examining the analgesic effects of TAP blocks in women receiving intrathecal morphine, on the other hand, have shown no significant benefit. Meta-analysis data based on 2 studies found pain scores on movement were reduced at 6 hours, but there was no difference in rest or dynamic pain scores at 12, 24, or 48 hours. Opioid use and maternal satisfaction scores were also similar in both TAP block and control subjects.
Since the 2012 meta-analyses, 3 further studies\textsuperscript{237–239} have been published that confirm that the addition of TAP blocks to intrathecal morphine does little to improve the post–cesarean delivery pain experience (Table 5).

**TAP block versus intrathecal morphine in cesarean delivery**

Most studies that have compared intrathecal morphine to TAP blocks show that intrathecal morphine provides slightly better post–cesarean delivery analgesia\textsuperscript{227–230,240} (Table 5). Meta-analysis\textsuperscript{230} shows that women receiving intrathecal morphine had a longer time to first analgesic request (8 vs 4 hours), lower 24-hour opioid consumption (mean difference, 8 mg IV morphine), and lower dynamic pain scores at 24 hours (mean difference, 0.98 on a 0- to 10-point scale) but not at rest. Postoperative nausea and vomiting were more common in the women receiving intrathecal morphine\textsuperscript{230}; however, no differences in pruritus, sedation, or respiratory depression were seen.

**TAP block versus other analgesic strategies in cesarean delivery**

There are limited data comparing TAP block with other analgesic modalities in cesarean delivery. In 1 nonrandomized study, TAP blocks were administered at patients' request after cesarean

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{image.png}
\caption{Ultrasound-guided TFP block. A, Preinjection image. The needle is advanced in an anterior-to-posterior direction, aiming to pierce the TAM where it tapers off into its aponeurosis. The target for needle tip position is immediately deep to TAM as indicated by the asterisk. B, Postinjection image. Correct needle tip position is indicated by formation of a visible pocket of local anesthetic (LA) expanding in the plane between TAM and the transversalis fascia, which lines the deep surface of TAM. The II-N and IH-N lie in this location immediately superior to the iliac crest (inset picture). IH-N indicates iliohypogastric nerve; II-N, ilioinguinal nerve; LA, local anesthetic. Reproduced with permission from KJ Chin Medicine Professional Corporation.}
\end{figure}
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TAP blocks in cesarean delivery under general anesthesia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tan et al,231 2012</td>
<td>N = 40, elective LSCS. Intraop: GA + IV morphine 0.15 mg/kg. Postop: IV PCA morphine.</td>
<td>Bilateral USG lateral TAP blocks using 20 mL 0.25% levobupivacaine per side at the end of surgery</td>
<td>No TAP blocks.</td>
<td>No sig differences in rest or dynamic pain scores between groups. Sig lower morphine use in TAP vs control group at 24 h (mean 12.3 vs 31.4 mg).</td>
<td>No sig differences in nausea or vomiting, sedation, or satisfaction between groups.</td>
</tr>
<tr>
<td>Eslamian et al,232 2012</td>
<td>N = 48, elective LSCS. Intraop: GA + IV morphine 0.1 mg/kg + sufentanil 15 μg. Postop: PR diclofenac 100 mg every 24 h + IV tramadol 50 mg every 4 h pm</td>
<td>Bilateral LMG TAP blocks using 15 mL 0.25% levobupivacaine per side at the end of surgery.</td>
<td>No TAP blocks.</td>
<td>Sig lower rest pain scores in TAP vs control group up to 12 h, but not at 24 h. Sig lower dynamic pain scores in TAP vs control group at time points up to 24 h. Sig lower tramadol use in TAP vs control group (mean 75 vs 250 mg). Sig longer time to 1st opioid use in TAP vs control group (mean 210 vs 30 min).</td>
<td></td>
</tr>
<tr>
<td><strong>TAP blocks in cesarean delivery under neuraxial anesthesia without intrathecal morphine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baaj et al,233 2010</td>
<td>N = 40, elective LSCS. Intraop: spinal anesthesia; no IT morphine. Postop: IV PCA morphine. No MMA.</td>
<td>Bilateral USG lateral TAP blocks using 20 mL 0.25% ropivacaine per side at the end of surgery.</td>
<td>Sham TAP blocks with 0.9% saline.</td>
<td>Lower pain scores in TAP group vs control group. Sig lower morphine use at 24 h in TAP vs control group (mean 25.9 vs 62 mg).</td>
<td>Sig less nausea and vomiting in TAP vs control group (5% vs 10.5%).</td>
</tr>
<tr>
<td>Belavy et al,234 2009</td>
<td>N = 47, elective LSCS. Intraop: spinal anesthesia; no IT morphine. PR diclofenac 100 mg + PR acetaminophen 1 g. Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h + PO ibuprofen 400 mg every 8 h.</td>
<td>Bilateral USG lateral TAP blocks using 20 mL 0.5% ropivacaine per side at the end of surgery.</td>
<td>Sham TAP blocks with 0.9% saline.</td>
<td>No sig difference in pain scores over 24 h in TAP vs control group (2.7 vs 2.3). Sig lower morphine use in TAP vs control group at 24 h (18 vs 31.5 mg). Sig shorter time to 1st opioid use in TAP vs control group (median 2 vs 3 h).</td>
<td>Sig higher patient satisfaction in TAP vs control group (9.6 vs 7.7 out of 10). Sig fewer patients received antiemetics in TAP vs control group</td>
</tr>
<tr>
<td>McDonnell et al,235 2008</td>
<td>N = 50, elective LSCS. Intraop: spinal anesthesia; no IT morphine. PR diclofenac 1 mg/kg + PR acetaminophen 1 g. Postop: IV PCA morphine + PO acetaminophen 1 g + PR diclofenac 100 mg every 18 h.</td>
<td>Bilateral LMG TAP blocks using 1.5 mg/kg ropivacaine per side at the end of surgery.</td>
<td>Sham TAP blocks with 0.9% saline.</td>
<td>Sig lower rest and dynamic pain scores in TAP vs control group up to 12 h but not beyond. Sig lower morphine use in TAP vs control group at 0-12 h (6 vs 33 mg), at 12-24 h (3 vs 19 mg) but not at 24-36 h or 36-48 h. Sig lower morphine use in TAP vs control group over 48 h. Sig longer time to 1st morphine use in TAP vs control group (median 220 vs 90 min).</td>
<td>Sig lower incidence of sedation in TAP vs control group (0% vs 36%). No sig difference in nausea between groups.</td>
</tr>
<tr>
<td>Study</td>
<td>Standardized Management</td>
<td>Intervention</td>
<td>Comparator</td>
<td>Analgesic Outcomes</td>
<td>Other Outcomes</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>TAP blocks in cesarean delivery under neuraxial anesthesia with intrathecal morphine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McNamara et al, 227, 2011</td>
<td>N = 80, elective LSCS. Intraop: spinal anesthesia. Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h + PR diclofenac 100 mg every 12 h.</td>
<td>Group I: Bilateral LMG TAP blocks with 1 mg/kg 0.375% bupivacaine per side at end of surgery + IT morphine 100 μg. Group II: Bilateral LMG TAP blocks with 1 mg/kg 0.375% bupivacaine per side at end of surgery; no IT morphine.</td>
<td>Group III: IT morphine 100 μg + sham TAP blocks. Group IV: no IT morphine + sham TAP blocks.</td>
<td>Sig difference in rest pain scores between groups at 6 h (0.9 vs 1.6 vs 2.9 vs 3.1; group I vs III vs IV vs II) and 24 h (1 vs 1.2 vs 2 vs 2.7; group III vs I vs IV vs II), but not at 48 h. Sig difference in dynamic pain scores between groups at 6 h (2 vs 2.75 vs 5.15 vs 5.2; group I vs III vs IV vs II), but not at 24 h or 48 h. Sig difference in morphine use between groups at 6 h (4.0 vs 5.0 vs 8.0 vs 12.0 mg; group III vs I vs IV vs II), 12 h (2.0 vs 5.0 vs 6.0 vs 10.5 mg; group III vs I vs IV vs II), 24 h (5.0 vs 6.0 vs 9.5 vs 15.0 mg; group I vs III vs IV vs II), but not at 48 h. No sig difference in patient satisfaction between groups.</td>
<td>Highest use of anti-emetics in group I. Pruritus most common in group III.</td>
</tr>
<tr>
<td>Costello et al, 236, 2009</td>
<td>N = 50, elective LSCS. Intraop: spinal anesthesia + IT morphine 100 μg + IV ketorolac 30 mg + PR acetaminophen 1.3 g. Postop: PO acetaminophen 1 g every 6 h + PO diclofenac 50 mg + SC/PO morphine prn.</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0.375% ropivacaine per side at end of surgery.</td>
<td>Sham TAP blocks with 0.9% saline.</td>
<td>No sig difference in rest or dynamic pain scores in TAP vs control group at any other time point up to 48 h. No sig difference in opioid use between groups.</td>
<td>No sig difference in nausea, sedation, dizziness, pruritus, or satisfaction between groups.</td>
</tr>
<tr>
<td>Lee et al, 237, 2013</td>
<td>N = 51, elective LSCS. Intraop: CSE + IT morphine 250 μg. Postop: PO acetaminophen 1 g every 6 h prn, IV ketorolac or PO ibuprofen 800 mg every 6 h prn, PO acetaminophen 325 mg-oxycodeone 5 mg 2 tabs every 6 h prn.</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0. 5% ropivacaine per side at end of surgery.</td>
<td>Sham TAP blocks with 0.9% saline.</td>
<td>Sig lower pain scores in TAP vs control group at 2 h at rest (mean 0.5 vs 2.8) and movement (mean 1.9 vs 4.9). No sig differences in rest or dynamic pain scores between groups at 24 h and 48 h. Sig lower analgesic use in TAP vs control group in PACU. No sig differences in analgesic use at 48 h, or time to 1st analgesic use between groups.</td>
<td>No sig differences in nausea, sedation, dizziness, pruritus, or satisfaction between groups.</td>
</tr>
<tr>
<td>Singh et al, 238, 2013</td>
<td>N = 59, elective LSCS. Intraop: spinal anesthesia + IT morphine 150 μg + IV ketorolac 30 mg Postop: PO acetaminophen 650 mg every 6 h + IV ketorolac every 6 h, PO oxycodeone 5-10 mg every 4 h prn.</td>
<td>Group I: Bilateral USG lateral TAP blocks with 1.5 mg/kg 0.5% ropivacaine per side at end of surgery. Group II: Bilateral USG lateral TAP blocks with 0.75 mg/kg 0.5% ropivacaine per side at end of surgery.</td>
<td>Group III: sham TAP blocks with 0.9% saline.</td>
<td>Sig lower dynamic pain scores in group I vs both group II and III at 6 h and 12 h, but not between group II and III. No sig difference in dynamic pain in patients at 24 h between groups. No sig difference in analgesic use between groups.</td>
<td>No sig difference in sedation, pruritus, nausea, quality of recovery, or patient satisfaction between groups.</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Year</td>
<td>N</td>
<td>Group 1</td>
<td>Group 2</td>
<td>Group 3</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>---</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>McKeen et al.</td>
<td>2014</td>
<td>83</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0.25% ropivacaine per side at end of surgery.</td>
<td>Sham TAP blocks with 0.9% saline.</td>
<td>No sig differences in rest or dynamic pain scores at 24 h between groups. No sig differences in opioid use over 24 h between groups.</td>
</tr>
<tr>
<td>TAP blocks versus intrathecal morphine in cesarean delivery under neuraxial anesthesia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kanazi et al.</td>
<td>2010</td>
<td>57</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0.375% bupivacaine per side at end of surgery.</td>
<td>IT morphine 200 μg + sham TAP blocks with 0.9% saline</td>
<td>Sig higher visceral pain scores in TAP vs IT morphine group at 0-4 h but not beyond. Sig higher tramadol use in TAP vs IT morphine group at 0-12 h (median 0 vs 0), but not 12-24 h (median 0 vs 0). Sig shorter time to 1st analgesic use in TAP vs IT morphine group (median 4 vs 8 h).</td>
</tr>
<tr>
<td>Loane et al.</td>
<td>2012</td>
<td>66</td>
<td>Bilateral USG lateral TAP blocks with 1.5 mg/kg 0.5% ropivacaine per side at end of surgery.</td>
<td>100 μg IT morphine + sham TAP blocks with 0.9% saline</td>
<td>Sig higher rest and dynamic pain scores in TAP vs IT morphine group at 10 h, but not at other time points. Sig higher morphine use in TAP vs IT morphine group at 10-24 h (mean 7.5 vs 2.7 mg), but no sig difference at &lt;10 h.</td>
</tr>
<tr>
<td>Canovas et al.</td>
<td>2013</td>
<td>90</td>
<td>Group I: Bilateral USG lateral TAP blocks with 20 mL 0.5% levobupivacaine per side at end of surgery + IT fentanyl 10 μg.</td>
<td>Group II: IT fentanyl 10 μg. Group III: IT morphine 100 μg.</td>
<td>Sig lower rest pain scores in TAP group vs group II and III at 12 h (mean 1.9 vs 4.3 vs 2.1) and 24 h (2.3 vs 4.8 vs 4.7). Sig lower number of PCA boluses in 24 h in TAP group vs group II and III (mean 5 vs 38 vs 10). Time to 1st opioid use was longest in TAP group vs group II and III (mean 13.2 vs 2 vs 9.3 h).</td>
</tr>
<tr>
<td>TAP blocks versus wound infiltration in cesarean delivery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telnes et al.</td>
<td>2015</td>
<td>57</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0.25% bupivacaine per side + sham infiltration at end of surgery.</td>
<td>Wound infiltration with 20 mL 0.25% bupivacaine + sham TAP blocks at end of surgery.</td>
<td>No sig differences in rest and dynamic pain over 48 h between groups. No sig difference in morphine use in TAP vs infiltration group over 48 h (mean 41 vs 38 mg). No sig difference in time to 1st analgesic use in TAP vs infiltration group (mean 46 vs 64 min).</td>
</tr>
</tbody>
</table>

Continued next page
<table>
<thead>
<tr>
<th>Study</th>
<th>Standardized Management</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Analgesic Outcomes</th>
<th>Other Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chandon et al, 242 2014</td>
<td>N = 65, elective LSCS. Intraop: spinal anesthesia; no IT morphine. Postop: PO acetaminophen 1 g every 6 h + PO ketoprofen 50 mg every 6 h + nefopam 20 mg every 6 h.</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0.375% levobupivacaine at end of surgery.</td>
<td>Surgical insertion of wound catheter, followed by infusion of 5 mL/h of 0.125% levobupivacaine.</td>
<td>No sig differences in rest and dynamic pain scores over 48 h between groups. No sig difference in morphine use between groups.</td>
<td>1 episode of LAST seizures following TAP block, leading to early study termination. Sig more nausea and vomiting in TAP group. No sig differences in sedation, pruritus, satisfaction, or length of hospital stay between groups.</td>
</tr>
<tr>
<td>Aydogmus et al, 243 2014</td>
<td>N = 70, elective LSCS. Intraop: spinal anesthesia; no IT morphine. Postop: IM diclofenac 75 mg prn, IV tramadol 50 mg prn.</td>
<td>Bilateral USG lateral TAP blocks with 20 mL 0.25% levobupivacaine per side at end of surgery.</td>
<td>Wound infiltration with 40 mL 0.25% levobupivacaine at end of surgery.</td>
<td>Sig lower pain scores in TAP vs infiltration group at 2 h (median 4 vs 5), 6 h (median 4 vs 5), 12 h (2 vs 5), 24 h (2 vs 4). Sig longer time to 1st analgesic use in TAP vs infiltration group (mean 6.1 vs 2.6 h).</td>
<td>No sig difference in patient satisfaction between groups.</td>
</tr>
<tr>
<td>Quadratus lumborum blocks versus systemic analgesia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blanco et al, 207 2015</td>
<td>N = 48, elective LSCS. Intraop: PR diclofenac 100 mg + IV acetaminophen 1 g. Postop: IV PCA morphine + PO acetaminophen 1 g every 6 h + PO diclofenac 50 mg every 8 h.</td>
<td>Bilateral USG QL blocks (QLBs) with 0.2 mL/kg 0.125% bupivacaine per side at end of surgery.</td>
<td>Sham QLBs with 0.9% saline.</td>
<td>Sig lower rest and dynamic pain scores in QLB vs control group at all time points up to 48 h (except rest pain at 24 h). Sig lower morphine use in QLB vs control group at 6 h (median 2 vs 7 mg) and 12 h (median 8 vs 14 mg), but not at 24 h and 48 h.</td>
<td>No sig differences in sedation, nausea, or pruritus between groups.</td>
</tr>
<tr>
<td>II-IH blocks in cesarean delivery without intrathecal morphine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bunting and McConachie, 244 1988</td>
<td>N = 26, elective LSCS. Intraop: GA + IV fentanyl 100 μg. Postop: papaveretum pm.</td>
<td>Bilateral LMG II-IH blocks using 10 mL 0.5% bupivacaine per side at end of surgery.</td>
<td>No II-IH blocks.</td>
<td>Sig lower pain scores at all time points up to 24 h in II-IH vs control group. Sig lower analgesic use in II-IH vs control group.</td>
<td>No sig differences in pain scores or pruritus between groups.</td>
</tr>
<tr>
<td>Bell et al, 245 2002</td>
<td>N = 59, elective LSCS. Intraop: spinal or epidural anesthesia; no IT morphine. Postop: IV PCA morphine. No MMA.</td>
<td>Bilateral LMG II-IH blocks using 12 mL 0.5% bupivacaine per side at end of surgery.</td>
<td>Sham II-IH blocks with 0.9% saline.</td>
<td>No sig difference in pain scores in II-IH vs control group (mean 1.7 vs 2.2). Sig lower morphine use in II-IH vs control group over 24 h (mean 48 vs 67 mg).</td>
<td>No sig differences in nausea or pruritus between groups.</td>
</tr>
<tr>
<td>Ganta et al, 246 1994</td>
<td>N = 62, elective LSCS. Intraop: GA. Postop: IM papaveretum in 1st 24 h.</td>
<td>Group I: preincisional bilateral LMG II-IH blocks using 10 mL 0.5% bupivacaine per side.</td>
<td>Group II: wound infiltration with 20 mL 0.5% bupivacaine. Group III: No local anesthetic.</td>
<td>Sig lower pain scores in group I vs III at 4-24 h. Sig lower analgesic use in group I vs III at 4-20 h. No sig difference in pain scores or analgesic use between group I and II.</td>
<td>There were sig differences in pain scores and analgesic use in group II vs III but only in the 1st 12 h.</td>
</tr>
<tr>
<td>Study</td>
<td>Authors</td>
<td>N</td>
<td>Intraoperative</td>
<td>Postoperative</td>
<td>Group I: Bilateral LMG II-IH blocks at end of surgery using 10 mL 0.5% bupivacaine per side.</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------</td>
<td>-----</td>
<td>----------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>II-IH blocks in cesarean delivery with intrathecal morphine</td>
<td>Vallejo et al.</td>
<td>34</td>
<td>Spinal anesthesia + IT morphine 150–200 μg.</td>
<td>IV ketorolac 30 mg x1 pm; PO acetaminophen 500 mg; oxycodone 5 mg; 2 tab every 6 h pm; or IV PCA morphine.</td>
<td>Bilateral LMG II-IH blocks at end of surgery using 10 mL 0.5% bupivacaine per side.</td>
</tr>
<tr>
<td>Wolfson et al.</td>
<td>2012</td>
<td>34</td>
<td>Spinal anesthesia + IT morphine 200 μg.</td>
<td>IV ketorolac 30 mg x1 pm; PO acetaminophen 500 mg; oxycodone 5 mg; 2 tab every 6 h pm; or IV PCA morphine.</td>
<td>Bilateral LMG II-IH blocks at end of surgery using 12 mL 0.5% bupivacaine per side.</td>
</tr>
</tbody>
</table>

All pain scores reported on a 0- to 10-point scale.

CSE indicates combined spinal-epidural anesthesia; II-IH, ilioinguinal = iliohypogastric; IT, intrathecal; LMG, landmark-guided; LSCS, lower-segment cesarean delivery; MMA, multimodal analgesia; PCA, patient-controlled analgesia; PO, oral; POD, postoperative day; PR, rectal; USG, US-guided.
delivery under combined spinal-epidural anesthesia with epidural morphine 2 mg. Women receiving TAP blocks had improved time to first analgesic and morphine consumption.

Bilateral US-guided lateral TAP blocks have also been compared with wound site infiltration in 3 studies of cesarean delivery under spinal anesthesia without intrathecal morphine. Two of the studies reported no difference in analgesic outcomes between groups, whereas the third found that TAP blocks reduced pain scores and increased time to first analgesic request.

Continuous TAP block in cesarean delivery

There are no randomized controlled studies to confirm the utility of continuous TAP catheters following cesarean delivery, although 1 case report suggests they may have a role if prolonged analgesia is required. The superior side-effect profile may make them preferable to epidural analgesia but must be balanced against the technical and logistical issues previously discussed.

QL Block in Obstetric Patients

To date, there is only 1 RCT of the US-guided QL block in the obstetric population. This demonstrated reduced opioid requirements and pain scores in the first 24 to 48 hours following cesarean delivery with spinal anesthesia (but without intrathecal morphine) when a posterior QL block was performed in addition to a multimodal analgesic regimen of acetaminophen and NSAIDs (Table 5). Further investigation is needed to define its role in this setting.

II-IH Nerve Block in Obstetric Patients

Four studies have examined the effect of bilateral landmark-guided II-IH blocks in patients undergoing cesarean delivery without intrathecal morphine. Three of the studies reported that II-IH blocks reduced analgesic requirements and pain scores compared with control subjects, but the fourth found no significant differences.

There are conflicting data on the value of adding II-IH blocks to intrathecal morphine in cesarean delivery. Vallet et al found that bilateral US-guided II-IH blocks did not improve postoperative analgesia or decrease opioid-related adverse effects (nausea, vomiting, and pruritus). In contrast, Wolfson et al reported that bilateral multi-injection landmark-guided II-IH nerve blocks produced lower pain scores and analgesic requirements, longer time to first analgesic use, and higher satisfaction scores compared with intrathecal morphine alone.

It has also been proposed that it may be more effective to combine TAP block with II-IH nerve block, given that these nerves are inconsistently blocked by US-guided TAP blocks. However, no studies have compared the analgesic efficacy of TAP and II-IH blocks in cesarean delivery. Finally, the potential of continuous II-IH nerve blockade for cesarean delivery analgesia has been highlighted in a small case series. Bilateral catheters were inserted under US guidance, and 0.2% ropivacaine at 4 mL/h was administered for 72 hours. Patients had minimal pain and analgesic requirements despite receiving no intrathecal morphine.

In summary, II-IH blocks have been used to treat post–cesarean delivery pain with varying success. The heterogeneity and small number of available studies make it difficult to conclude if this reflects failure rates inherent in the specific technique used or a true lack of efficacy in this setting. The addition of intrathecal morphine may also reduce the apparent analgesic benefit, as it does with TAP blocks. Iliinguinal-iliohypogastric blocks may be an alternative rescue block technique where other modalities have failed.

Rectus Sheath Block in Obstetric Patients

There are only isolated case reports of rectus sheath blocks in the obstetric setting. In 1 report, bilateral US-guided rectus sheath block at the level of the umbilicus was performed 3 days after surgery to relieve neuropathic incisional pain. In another report, bilateral landmark-guided rectus sheath block was performed after midline incision cesarean delivery under general anesthesia. Despite this, the patient continued to require large doses of opioids for analgesia. The utility of rectus sheath blocks for Pfannenstiel incisions is questionable. The posterior rectus sheath is deficient below the arcuate line, and the II and IH nerves have no relationship to the RAM, given the absence of a posterior rectus sheath below the arcuate line.

The Overall Role of Truncal Blocks in Obstetric Patients

At present, the greatest weight of evidence favors the use of TAP blocks over other abdominal wall blocks in cesarean delivery, although further studies on the QL block are awaited. As in the nonobstetric population, any attempt to summarize the literature on TAP blocks is hampered by the recent realization that the landmark-guided and US-guided approaches may differ in their mechanism of action. However, the vast majority of obstetric studies utilize the US-guided lateral TAP block, and the recommendations shown in Table 6 apply to this approach. The current evidence demonstrates that in women receiving general anesthesia or neuraxial anesthesia without intrathecal opioids TAP blocks improve postoperative analgesia in the first 24 hours and are at least as good as, if not better than, wound infiltration. Intrathecal morphine confers an improvement in pain scores and opioid consumption compared with TAP block, but this needs to be weighed against the increased risk of adverse effects, particularly nausea and vomiting. In women who do receive intrathecal morphine and multimodal analgesia, the benefit of TAP blocks is modest at best and confined to the early (6 hours) postoperative period. In these patients, TAP blocks may therefore be better suited as a rescue analgesic technique for severe breakthrough pain following surgery, rather than as a routine block in all patients. This was illustrated by a case series of TAP blocks administered for severe incisional pain after resolution of the spinal block following cesarean delivery. The blocks provided excellent pain relief for 10 to 19 hours and prevented further escalation in IV opioid requirements. Isolated case reports have also described the successful application of TAP blocks for intractable incisional neuropathic pain and pain from an abdominal wall hematoma following cesarean delivery, as well as abdominal wall pain during pregnancy. However, visceral pain will not be relieved by TAP blocks, and it is therefore important to determine the nature of pain (incisional or cramping) before proceeding.

**TABLE 6. Clinical Settings Where TAP Blocks Are Indicated for the Provision of Cesarean Delivery Analgesia**

<table>
<thead>
<tr>
<th>Setting</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>At time of surgery after wound closure</td>
<td>Cesarean delivery under general anesthesia; cesarean delivery with spinal anesthesia without the use of intrathecal morphine</td>
</tr>
<tr>
<td>In recovery or on postpartum floor</td>
<td>Rescue analgesic for severe incisional pain; postoperative analgesic technique for high or escalating IV opioid requirements</td>
</tr>
<tr>
<td>Patient-specific factors</td>
<td>NSAIDs contraindicated or withheld because of obstetric concerns; Opioid-dependent</td>
</tr>
</tbody>
</table>
SAFETY CONCERNS IN ABDOMINAL WALL BLOCKS

Reports of complications associated with abdominal wall blocks are fortunately relatively rare and can be divided into 3 main categories: needle or mechanical trauma, maldistribution of local anesthetic, and local anesthetic systemic toxicity (LAST).

Needle Trauma

The major concern with abdominal wall blocks, particularly the landmark-guided approaches where entry into the correct tissue plane is guided only by subjective tactile pops, is excessively deep needle insertion. Intraperitoneal injection per se is relatively harmless, apart from resulting in block failure. However, visceral injury has been reported with all the major truncal block techniques, including liver trauma following TAP block and intestinal trauma following II-IH block. Vascular injury resulting in pelvic and retroperitoneal hematoma has also been described with II-IH block and rectus sheath block, respectively. The use of US guidance should significantly minimize this risk, but misadventure may still occur if needle tip visualization is inadequate.

There have been no reports of neurological injury associated with truncal blocks to date, and this can be attributed to the fact that tissue planes, rather than nerves, are targeted and that any nerves in the target area are small and thus unlikely to be directly involved in needle trauma. For this reason, it is generally accepted that truncal blocks may be performed under general or neuraxial anesthesia.

Maldistribution of Local Anesthetic

Inadvertent femoral nerve block is a well-recognized complication of II-IH nerve block in both pediatric and adult populations; but it has also been reported with TAP block. This is more likely with the landmark-guided techniques as the mechanism is excessively deep injection of local anesthetic into the plane between transversus abdominis and transversalis fascia, which then tracks inferiorly under the iliopecto fascia to the femoral nerve and lumbar plexus. Lumbar plexus block is therefore also a possible consequence of the US-guided QL and TFP blocks, which specifically involve injection into the TFP close to psoas major. All patients receiving truncal blocks (with the exception of rectus sheath blocks) should be warned of the possibility of transient quadriceps weakness and appropriate precautions taken when mobilizing postoperatively.

Local Anesthetic Systemic Toxicity

Abdominal wall blocks have significant potential for LAST due primarily to the fact that the intermuscular tissue plane presents a large well-vascularized surface for local anesthetic absorption. Contributing factors include the use of relatively large injection volumes to ensure adequate spread and bilateral blocks to cover midline incisions. This is particularly pertinent in the obstetric population as physiological changes of pregnancy may increase the risk of LAST in parturients.

Several measures may help mitigate the risk of LAST and should be used whenever possible. Epinephrine will reduce peak local anesthetic plasma concentration and should always be added to the injectate solution. Ropivacaine and levobupivacaine are less cardiotoxic than racemic bupivacaine, and it is therefore logical to prefer their use. Doses with US-guided approaches should be lower than with landmark-guided approaches because they are associated with higher local anesthetic plasma concentrations. Local anesthetic doses can also be minimized by using more dilute concentrations (eg, ropivacaine 0.2%–0.25% instead of 0.5%), which do not appear to compromise analgesic efficacy. Lean body-weight dosing should be used in overweight subjects, and maximum recommended doses of local anesthetics always adhered to. Patients should also be closely monitored for at least 30 to 45 minutes because this is the average time to peak plasma concentration following truncal blocks. Consent Issues

In light of the small but real risk for serious complications, consent is an essential requirement before performing abdominal wall blocks. If preincisional blocks are not part of the anesthetic plan, it is prudent to obtain consent for postoperative rescue blocks in the event of significant pain. A United Kingdom-based survey of obstetric anesthesiologists found that only 65% of respondents obtained consent for TAP blocks; however, this may reflect the fact that general anesthesia for cesarean delivery is often done emergently with little or no time to adequately consent patients for a regional block.

CONCLUSIONS

Abdominal wall blocks, particularly when performed with US guidance, are technically simple and have favorable safety and side-effect profiles. They are therefore attractive alternatives to epidural and paravertebral blocks for truncal analgesia, particularly because they can be performed during general anesthesia and in the supine position. At the same time, their limitations must be recognized. The fixed analgesic duration of single-shot blocks is an issue because continuous catheter techniques, although feasible, are complex and cumbersome. Further research is awaited to see if local anesthetic additives or liposomal bupivacaine will prove to be a solution.

In addition, the extent of analgesia varies with the specific technique, and this must be matched to the surgical site. This applies in particular to the TAP block, which encompasses multiple approaches with different clinical applications. For example, the US-guided subcostal TAP should be used to cover supraumbilical incisions, whereas the US-guided lateral TAP block is best suited to incisions in the T10-T12 area. With the possible exception of the QL block and landmark-guided TAP block, abdominal wall blocks generally do not provide analgesia for incisions extending lateral to the anterior axillary line and provide limited additional benefit in surgeries with either a large component of visceral pain or only a small component of somatic pain. These factors, coupled with the interindividual variability in spread and efficacy observed in most studies, mean that these blocks are most useful as part of a multimodal analgesic regimen.

It is increasingly apparent that the abdominal wall is anatomically complex, particularly with regard to the relationships between muscles, fascial layers, and the planes that exist between them. Most abdominal wall blocks are based on injection into a particular tissue plane, and as the evolution of TAP blocks has shown, apparently small anatomical differences in needle tip placement can result in clinically significant differences between what seem to be otherwise similar techniques. When it comes to the efficacy of abdominal wall blocks, the devil may be in the details. We would therefore encourage investigators to be as specific as possible in their anatomical and technical descriptions going forward. We also recommend using block nomenclature that is simple yet informative and, ideally, reflects the anatomical basis of the block as accurately as possible.
REFERENCES


Chin et al.

Regional Anesthesia and Pain Medicine • Volume 42, Number 2, March-April 2017


79. Griffiths JD, Middle JV, Barron FA, Grant SJ, Popham PA, Royse CF. Transversus abdominis plane block does not provide additional benefit to multimodal analgesia in gynaecological cancer surgery. Anesth Analg. 2010;111:797–801.


hand-assisted nephrectomy: a randomized, placebo-controlled trial. Local Reg Anesth. 2014;7:11–16.


144. Schulte-Steinberg O. Regional Anesthesia in Children. Norwalk, CT: Appleton & Lange/Mediglobe; 1990.


